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Abstract
TIPE2 is a recently discovered regulator of immunity and inflammation. Here we describe a new function
of TIPE2 in the regulation of Ras signaling and Tumorigenesis. By using various stimuli and inhibitors in T
Cells and macrophages we discovered that TIPE2 is regulated at both the message and protein level by
inflammatory stimuli. TIPE2 mRNA is regulated in the short to intermediate term by an NF-Kappa B
induced micro RNA, and TIPE2 is also ubiquitylated and degraded, possibly by SCF-Beta TRCP.
Mechanistically TIPE2 interacts with and inhibits the Ras-interacting domain of the RalGDS family of Ras
effectors, leading to a loss of downstream Ral and AKT activity. TIPE2 deficiency led to increased
activation of Ral and AKT, resulting in resistance to cell death, increased migration, and dysregulated
exocyst complex formation. Overexpression of TIPE2 conversely induced cell death, affected actin
polymerization, and reduced exocyst complex assembly. TIPE2 was able to dramatically slow the growth
of Ras-induced tumors in mice, and the tumors were required to silence TIPE2 before they were licensed
to grow. TIPE2 additionally negatively regulates effectors of the mTOR pathway, including S6K and 4EBP1,
possibly via an interaction with, and destabilization of the mTORC2 complex. Crucially TIPE2 expression
is either completely lost or heavily down-regulated by human hepatocellular carcinoma. Thus, via its
simultaneous role as a regulator of inflammation and cancer, TIPE2 provides a mechanistic link between
these two disease states, and may be a potential drug target for both inflammatory and neoplastic
disease.
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ABSTRACT
THE ROLE OF TIPE2 IN THE REGULATION OF INFLAMMATION AND
TUMORIGENESIS
Derek Johnson
Youhai Chen
TIPE2 is a recently discovered regulator of immunity and inflammation.
Here we describe a new function of TIPE2 in the regulation of Ras signaling and
Tumorigenesis. By using various stimuli and inhibitors in T Cells and
macrophages we discovered that TIPE2 is regulated at both the message and
protein level by inflammatory stimuli. TIPE2 mRNA is regulated in the short to
intermediate term by an NF-B induced micro RNA, and TIPE2 is also
ubiquitylated and degraded, possibly by SCF-TRCP.

Mechanistically TIPE2

interacts with and inhibits the Ras-interacting domain of the RalGDS family of
Ras effectors, leading to a loss of downstream Ral and AKT activity. TIPE2
deficiency led to increased activation of Ral and AKT, resulting in resistance to
cell death, increased migration, and dysregulated exocyst complex formation.
Overexpression of TIPE2 conversely induced cell death, affected actin
polymerization, and reduced exocyst complex assembly.

TIPE2 was able to

dramatically slow the growth of Ras-induced tumors in mice, and the tumors
were required to silence TIPE2 before they were licensed to grow.

TIPE2

additionally negatively regulates effectors of the mTOR pathway, including S6K
and 4EBP1, possibly via an interaction with, and destabilization of the mTORC2
complex. Crucially TIPE2 expression is either completely lost or heavily downregulated by human hepatocellular carcinoma. Thus, via its simultaneous role as
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a regulator of inflammation and cancer, TIPE2 provides a mechanistic link
between these two disease states, and may be a potential drug target for both
inflammatory and neoplastic disease.
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Chapter 1
Introduction

1|Page

“Inflammation” is a diverse and nuanced process composed of
thousands of different reactions and molecules. This process is tightly controlled
in order to ensure that the body responds appropriately to a nearly infinite
number of infectious agents and dangerous conditions while still maintaining
proper bodily homeostasis. If this response is too weak, the body is overtaken by
infection and dies, if the response too potent, the weapons employed by the
immune system can permanently damage, or, in some cases, destroy the
host. The immune system has many tools and methods that it uses to modulate
and tweak its response in order to create an outcome with just enough duration
and intensity to end the external threat while dealing minimal damage to the
host. These tools range from soluble molecules that enter into the peripheral
circulation (cytokines, chemokines, etc.) to pro- and anti- inflammatory molecules
expressed on the surface of both immune and non-immune cells (TNFR,
TGFR, CTLA4 etc.) to various intracellular signaling molecules that can control
every process from secretion to metabolism to survival. With a careful balance
maintained between these myriad inputs, we arrive at a condition that we refer to
as “health”. Loss of proper regulation of inflammation results in inflammatory
disease. Inflammatory diseases afflict tens of millions of people every year
(CDC). While crude treatments such as glucocorticoids and non-steroid-antiinflammatory-drugs (NSAIDs) and more sophisticated treatments (soluble TNF
receptor, anti TNF monoclonal antibody) exist to treat such diseases, the
etiology of many such diseases is unknown (Hanauer, Lakatos). Central to
discovering treatments to these debilitating diseases is developing a better
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understanding of immuno-modulatory mechanisms that become dysregulated
during these disorders. While many of these regulatory mechanisms (PD-1,
CTLA4, SOCS-1) have been identified, the failure to control so many diseases of
excess inflammation indicates that there is much more to learn.
One family of molecules that has remained fairly thinly recognized for their
role as regulators of inflammation are small G proteins, specifically those of the
Ras family.

What Are Small GTPases?
Small GTPases are molecular switches that are capable of being in an “on” state
in which they are bound to Guanosine-Triphosphate (GTP), or an “off” state in
which they are bound to Guanosine-Diphosphate (GDP) (Figure 1.1). Their
binding to either of these nucleotides causes changes in the conformation of the
GTPase, which enables them to interact with and activate/deactivate different
effector molecules. Small GTPases have an intrinsic (albeit very weak) ability to
hydrolyze GTP to GDP, hence their possession of an internal “timer” which will
set off eventually. More typically these switches are activated by GuanineNucleotide-Exchange-Factors (GEFs) which “exchange” GTP into a binding
pocket previously occupied by GDP, hence turning “on” the GTPase. GTPaseActivating-Proteins (GAPs) activate the intrinsic GTPase activity of these proteins
(speeding up the timer), and convert bound GTP into GDP and turn “off” the
switch. It is the interplay between the GTPases, their GEFs and GAPs that
coordinate the functioning and modulation of many diverse biological processes.
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The Ras Superfamily
Ras is a GTPase that was initially found to be mutated in a wide variety of
cancers. Over time many similar GTPases were discovered to have a related 3D
structure to Ras, and the family now stands at over 150 total members. This
large superfamily can be further divided into at least six subfamilies; Ras, Rho,
Ran, Rab, Rheb, and ARF. While each of these families of small GTPases has
been extensively studied in the context of carcinogenesis, we are only beginning
to scratch the surface of how these related families of proteins are able to control
non-oncogenic processes such as immunity and inflammation.

There is

tremendous overlap in the functions performed by each of these groups of
GTPases, but the primary functions for each subfamily are summarized in Figure
1.2. The Ras subfamily, the first and most diverse of the subfamilies, can play a
vital role in the regulation of immunity and inflammation.

Ras
Ras is the founding and prototypical member of the small GTPase superfamily. It
regulates multiple cellular processes including cell survival, growth, and
differentiation. Upon stimulation by a growth factor or other extracellular stimuli,
a receptor tyrosine kinase (RTK) activates a Ras GEF such as Son of Sevenless
(SOS), which activates Ras by loading it with GTP allowing it to bind its
downstream effectors (Figure 1.3). Following activation, Ras triggers three
primary effector arms, the Raf/Mek/Erk pathway, the PI3K pathway, and the
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RalGDS signaling pathway. The RalGDS pathway activates Ral A and Ral B,
also members of the Ras GTPase family (to be discussed below).
ERK
When bound to Raf, Ras initiates the Raf/Mek/ERK MAPK signaling
cascade.

In this signaling cascade, each upstream molecule acts as a kinase

to phosphorylate and activate a subsequent downstream molecule, with an
eventual result being the modulation of transcription via the phosphorylation of a
variety of transcription factors. ERK plays a crucial role in cell proliferation and
survival. It is activated in lymphocytes downstream of TCR and BCR stimulation
(Donahue 2007). ERK activation can inhibit Fas-mediated apoptosis in T cells
(Holmstro 2000). The production of the vital cytokine IL-2 by T cells is dependent
upon ERK activation (Tsukamoto 1999, Koike 2003), as is the regulation of
glucose metabolism following TCR stimulation (Marko 2010). Diacylglycerol, an
important second messenger in the activation of Ras and ERK signaling, plays
crucial roles in T cell responses and Fc receptor-mediated phagocytosis ( Riese
2011, Shin 2012, Botelho 2009). Finally, ERK signaling is also important in TLRmediated chemokine production in dendritic cells (Mitchell 2010).
PI3K
Class I PI3K enzymes are composed of a regulatory (p85) and catalyitc (p110)
subunit. The catalytic subunit has a Ras binding domain and can be activated by
GTP-bound Ras. Upon activation, PI3K converts PIP2 to PIP3, which can serve
as a docking motif for proteins containing PH domains. Within the immune
system, PI3K plays crucial roles in the activation and functioning of all immune
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cells. PI3K regulates cytokine responsiveness and functions both in effector and
regulatory T cells, and mice with PI3K deficient T cells have several immune
defects (Sasaki 2000). The downstream PI3K target mTOR determines whether
T cells become activated or undergo anergy (Zheng 2007). PI3K is also crucial
for proper functioning of B cells (Shin 2012, Heidt 2008), NK cells (Ackerman
2011), dendritic cells, mast cells ( Wai 2008), macrophages, and neutrophils
(Sasaki 2000).

Rap
The Rap proteins share approximately 50% sequence homology to Ras, and
have an identical amino acid sequence in their effector loops. While there are
multiple Rap proteins, Rap1a and Rap1b are the best understood. It was initially
hypothesized that Rap1 functioned as a direct inhibitor of Ras by competition for
substrate binding. This idea has since been revised as it has become clear that
Rap1 has its own set of effector proteins and exists in completely different
signaling pathways than does Ras. Rap1 has been implicated in the activation of
integrin-mediated adhesion (Cirillo 1991, Tsukamoto 2004), establishment of
polarity (Shimonaka 2003, Schwamborn 2004), cell proliferation, and the control
of cell-cell interactions (Gerard 2007). The innate immune system has a
requirement for Rap1 in both macrophages (Katagiri 2000) and dendritic cells
(Caron 2000). In T cells, Rap1 is crucial for chemokine-induced polarization
(Gerard 2007, Katagiri 2004), and in B cells it regulates cell spreading and
adhesion (Mcleod 2004).

Rap1 is a potent activator of LFA1 (Katagiri 2000),
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and at least 3 different second messengers can activate Rap: i.e., cAMP,
calcium, and diacylglycerol.
Rap1a
Due to having 90% sequence homology, Rap1a and Rap1b were originally
assumed to serve redundant roles in the body. However experiments with
knockout and transgenic mice have increased our understanding of Rap1
function, as well as the specific and separate functions carried out by Rap1a and
1b. As mentioned above Rap1a was initially thought to exist to antagonize Ras
signaling. This initial hypothesis was supported by the observation that large
quantities of activated Rap1a are found in anergic T cells, and that activation of
CD28

by antibody binding inhibits the

induction of

Rap1a

by TCR

stimulation. Additionally in Jurkat T cells, active Rap1a expression inhibits
activation of ERK and induction of IL-2 gene expression (Boussiotis 1997). The
assumption from these results was that suppression of Rap1 expression is
required for a maximal T cell response. Nevertheless the theory that Rap1a
inhibits lymphocyte activation has been called into question by the generation of
transgenic mice expressing constitutively active Rap1a. Rap1a transgenic mice
expressing active Rap1a do not have deficiencies with either Ras signaling or T
cell activation (Sebzda 2002). Rap1a deficient T Cells were not anergic, but
surprisingly had an enhanced TCR response. Additionally, activation of Rap1a
caused T cells to bind more strongly to firbronectin, and induced strong activation
of 1 and 2 integrins, a process that generally requires antigen receptor binding
to induce. In contrast to the transgenic mice, Rap1a null mice had lymphocytes
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that were defective in adhesion to fibronectin and ICAM coated plates. T Cells
from Rap 1a null mice had impaired polarization following CD3 stimulation, but
these

mice

had

otherwise

healthy

lymphocyte

function

(Duchniewicz

2006). Macrophages from Rap1a knockouts had increased haptotaxis but
reduced chemotaxis, and had an increase in FcR-mediated phagocytosis.
Neutrophils from these mice produce reduced amounts of superoxide in
response to fMLP stimulation, which is likely due to the fact that Rap1a interacts
with the p22 subunit of NADPH oxidase in neutrophils (Li 2007).
Rap1b
Since Rap1b is highly expressed in B cells, Rap1b null mice were created to
understand the role of Rap1b in B cells (Chu 2008). Rap1b knockout mice have
reduced T-dependent, but normal T-independent humoral responses. B cells
from these mice have a reduction in migration in response to chemokines, and
have reduced homing to lymph nodes (Chrzanowska-Wodnicka 2008) Lung
endothelial cells from these mice show delayed healing in a wound-healing assay
(Chrzanowska-Wodnicka 2008). These mice had fewer pre-B cells in the bone
marrow, although splenic B cell proliferation was not affected. Additionally, mice
have been generated that lack the Rap1 Gap SPA1 and loss of this enzyme
(resulting in increased Rap1 activity) in hematopoietic and peripheral T cells
resulted in antigen-induced T cell anergy. Rap1b is also the primary isoform
expressed in NK cells, and may play a role in cytokine and chemokine production
in these cells (Awasthi 2010). Thus, in vivo, Rap1 is crucial for proper
functioning and development of T and B lymphocytes.
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Ral
The Ral (Ras-like) family of small GTPases is composed of two isoforms, Ral A
and Ral B, which share 85% protein sequence identity between them and
approximately 50% homology with Ras. Ral proteins have six known GEFs, four
of which are of the RalGDS family (RalGDS, RGL1, RGL2, RGL3) and are
primarily activated by upstream Ras signaling. Ral A and Ral B are highly
pleiotropic and impact many diverse signaling pathways within the cell. The Ral
proteins have many downstream binding partners that they interact with in order
to modulate cellular conditions and respond to extracellular signals. The primary
effectors are Ralbp1, the exocyst complex, and phospholipase D. In addition the
RalGDS family itself has the capacity to act as a scaffold to activate the Ser/Thr
Kinase AKT and promote cell survival and proliferation (Hao 2008).

RalBP1
Also known as RLIP76 and RIP (Ral interacting protein), RalBP1 is a nonABC multi-functional membrane transport protein that is responsible for the
majority of glutathione electrophile conjugate export in mammalian cells. This
transporter is responsible for a large amount of chemotherapeutic drug removal
from cancerous cells, and provides protection from a variety of forms of oxidative
damage or radiation-induced stress. RalBP1 has been linked to migration,
endocytosis of multiple receptor ligand pairs including TGF, and has GAP
activity towards some RHO family GTPases. Inhibition of RalBP1 with an
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antibody directed towards an extracellular region of the molecule induced
apoptosis in target cells. Also autoantibodies to the C terminal region of RalBP1
are associated with several immune mediated diseases such as Behçet disease,
SLE, and carotid atherosclerosis (Margutti 2008). Ralbp1 is crucial for the proper
expression of the transcription factor hsf-1, which is necessary for the expression
of many heat shock proteins, which are essential for cell survival under many
infectious conditions.
Exocyst
The exocyst complex is a tethering complex that exists to tether intracellular
vesicles to the plasma membrane prior to vesicular fusion during polarized
exocytosis. It is an octameric complex that exists in two parts, a three-member
complex, which exists on the vesicle being trafficked, and a five-member
complex that exists on the plasma membrane. Ral binds to and induces fusion
between members of each of these complexes, Exo84 on the vesicular complex,
and sec5 on the membrane complex. The exocyst complex plays a central role
in polarized exocytosis. Additionally the exocyst has been shown to play a role in
ciliogenesis,

cytokinesis,

wound

healing,

and

cell

migration

(Rosse

2006). Moreover one study has shown that the exocyst complex is needed for
appropriate NK cell degranulation and proper NK cell cytotoxicity (Sanchez
2011). Recently it has been reported that RalB and Exo84 can assemble to
autophagosomes and initiate autophagy (Bodemann 2011). RalB is also capable
of inducing an interaction between sec5 and the non-canonical IKK TBK1,
resulting in the activation of TBK1 and the downstream viral defense and survival
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pathways it controls (Chien 2006). A systems biology approach to assessing
pieces of the drosophila phagosome identified components of the exocyst
complex (Stuart 2007) as being involved in phagosome function. Being crucial
for a variety of key processes involving cell polarization, the exocyst complex and
its multiple components will likely be recognized to play an even more vital role
within the immune system in the future.
PLD
Phospholipase D (PLD) is an enzyme that hydrolyses phosphatidylcholine into
phosphatidic acid. PLD plays an important role in the internalization and
recycling of receptors. Both RalA and RalB can interact with PLD, though it is
the RalA interaction with phospholipase D positively regulates FcR mediated
phagocytosis (Corrotte 2010). PLD, via phosphatidic acid production, can
activate the central kinase mTOR, and this activation can be modulated by RalA
(Xu 2011).
TIPE2
A correlation between inflammation and cancer has been known to exist for
some time, but the mechanistic basis for this has not been clear. With strong
connections to neoplastic disease, as well as the regulation of inflammation and
the immune system, it is logical to consider that the Ras family and its effectors
and regulators could compose part of the mechanistic connection between these
two disease states. Work presented here will demonstrate that TIPE2 provides
one such mechanistic connection. TIPE2 is a member of the TNFAIP8 family of
proteins.
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TNFAIP8 Family
The Tumor Necrosis Factor Alpha Induced Protein Eight (TNFAIP8) family
of proteins, is a group of four proteins (TNFAIP8, TIPE1, TIPE2, and TIPE3) that
have to date been very thinly studied. TNFAIP8 is a roughly 20KD cytosolic
protein that sensitizes cells to glucocorticoid induced cell death (Woodward
2010) but suppresses TNF- mediated apoptosis (Laliberte 2010). TNFAIP8 has
been correlated with cancer progression and poor cancer prognosis in certain
types of cancer (Romanuik 2009). Very little is currently known about TIPE1 and
TIPE3.

TIPE2
Tumor necrosis factor alpha induced protein 8 like-2 or TNFAIP8L2 or
TIPE2 is a recently discovered member of the TNFAIP8 family of proteins. It was
discovered by comparing the gene expression profiles of spinal cord tissue from
healthy mice with that of mice with induced experimental autoimmune
encephalomyelitis or EAE, a mouse model for multiple sclerosis. The inflamed
EAE spinal cord tissue expressed large amounts of TIPE2, piquing interest in the
gene and further study which eventually resulted in the creation of a TIPE2
knockout mouse via germ line gene targeting (Sun 2008). The loss of TIPE2
proved to be an extremely debilitating mutation for these mice. TIPE2 deficient
mice develop normally but are prone to many inflammatory diseases which are
characterized by heightened inflammatory cytokine production, sensitivity to
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septic shock, and premature death.

These mice had extraordinarily high levels

of circulating cytokines, and had a larger number of both lymphocytes and
monocytes, resulting in splenomegaly (despite the mice themselves being
significantly smaller than their wild type counterparts). TIPE2 is down-regulated
in peripheral blood mononuclear cells in patients suffering from lupus (Li, 2009)
and hepatitis (Xi, 2011), and is upregulated in kidneys of diabetic rats (Zhang
2010). Additionally a recent paper has indicated that TIPE2 may provide a
protective function against ischemia/reperfusion injury following a stroke (Zhang
2012).
TIPE2 is expressed constitutively and at high levels in all immune cells
and shows inducible expression in fibroblast cell lines (Sun 2008). The loss of
TIPE2 correlates with increased levels of IkB degradation and increased nuclear
localization of NF-B family members.

Likewise overexpression of TIPE2

reduces the level of NF-B activity in response to TNF treatment. Knockdown
of TIPE2 resulted in increased phospho- JNK, phospho- p38, and c-Fos
signaling.

TIPE2 can be endogenously pulled down with caspase 8 in

macrophage cell lines. Caspase 8 has been previously shown to activate NF-kB
through a BCL10 / MALT1 complex (Su 2005). Knockdown of TIPE2 in EL4 T
Cells results in resistance to FasL induced cell death, while TIPE2 knockout T
Cells are resistant to activation induced cell death. TIPE2 knockout T cells
develop normally but produce more tetramer positive CD8+ T cells in response to
LCMV

infection

stimulation.

and

produce

more

cytokines

following

CD3/CD28

TIPE2 knockout macrophages produce more cytokines when
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exposed to TLR ligands. TIPE2 has recently been shown to bind to and inhibit
the small GTPase Rac1.

By inhibiting Rac1 TIPE2 inhibits phagocytosis in

macrophages (Wang 2012). Due to its regulation of such central and important
immunological pathways, TIPE2 plays a role in regulating both the innate and the
adaptive arms of the immune system
The TIPE2 protein has a very unique conformation, with no significant
homology to anything previously crystalized and catalogued. It is composed
solely of six alpha helices, which are arranged into a bowl-like shape, with the
inside faces of the alpha helices (inside of the bowl) possessing very
hydrophobic residues, while the outer faces of the alpha helices (outside of the
bowl) possess highly charged residues (Zhang 2009). While TIPE2 was thought
to have a DED domain due to interacting with Caspase 8 as well as due to high
homology with DED domains, the crystallization of TIPE2 has shown that it does
not in fact possess a DED domain, but instead has an odd DED “mirror image”
domain. Due to its potent effects on the immune system and inflammatory state,
its preferential expression in lymphoid and myeloid cell types, and its unique and
never before seen 3D structure, further knowledge

of TIPE2 function and

regulation could be crucial towards creating future treatments for a wide variety
of diseases.
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Hypothesis and Specific Aims
Understanding the mechanisms involved in generating an immune
response is a crucial component of creating new treatments for nearly every
disease known to man, as well as understanding how environmental factors can
affect health, and even how to make better and more efficacious vaccines.
TIPE2 appears to be a crucial piece of this puzzle, and will be of importance in
unraveling the mysteries of the immune system, and how it communicates and
orchestrates cellular actions in conjunction with the rest of the body. TIPE2 itself,
a modified TIPE2, or an ability to choose when and where TIPE2 is expressed
may all become viable treatments for any number of diseases at some point in
the future. Thus the specific aims were to understand both the regulation of
TIPE2, as well as the molecular mechanism(s) of its action in regulating cellular
processes.
The work described in Chapter 2 begins to narrow down the way in which
TIPE2 is regulated within the immune system. Both T Cells and macrophages
respond to stimulation by heavily reducing TIPE2 message levels. This reduction
in TIPE2 expression was both dependent upon NF-KB activity as well as
transcription not being blocked, drawing the conclusion that TIPE2 is regulated
by an NF-KB induced micro RNA in response to inflammatory signal reception by
both T lymphocytes as well as macrophages.

This work has been further

investigated and preliminary evidence indicates that mir21 is the crucial
microRNA regulating TIPE2.

In addition we provide evidence that TIPE2 is

ubiquitylated and degraded in response to these same TLR signals, and provide
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indications that SCF-TRCP may be the E3 ligase responsible for TIPE2
ubiquitylation and degradation.
In Chapter 3 the mechanistic underpinnings of TIPE2 began to be
investigated. TIPE2 interacts with and inhibits the activity of RGL1 and RalGDS,
both GEFS for the Ral family of small GTPase. These GEFs are activated by the
binding of Ras, which TIPE2 interrupts, and we went on to exhaustively
demonstrate that a multitude of downstream Ral effector pathways were impaired
by the presence of TIPE2. RGL1 and RalGDS also possess certain non GEF
functions, such as providing scaffolding activity for PDK1 and AKT, allowing
PDK1 to phosphorylate and activate AKT. This function was also inhibited by
TIPE2. We then went on to test the role of TIPE2 in tumor formation, and found
that TIPE2 delayed the appearance of tumors, and had to be silenced (via an
unknown mechanism) by the tumors in order for them to grow. We also went on
to demonstrate that TIPE2 is heavily downregulated in the hepatocytes of human
hepatocellular carcinoma patients. This data indicates that TIPE2 may play a
role in tumor suppression as well as in control of the immune system, or, possibly
play a role in anti-tumor immunity.
The data presented in Chapter 4 continues to investigate the molecular
mechanism of TIPE2s multitude of diverse yet potent phenotypes. The data
demonstrates that TIPE2 is capable of heavily interfering with, and reducing,
signaling through the mTOR pathway. This is likely occurring through a specific
and highly acute reduction of Rictor by TIPE2. It is possible that this is occurring
through a binding and sequestration of GBL, an interaction which is
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demonstrated in this chapter. This data indicates that TIPE2 is affecting the
nutrient sensing pathway within the immune system, and is therefore likely
affecting a plethora of functions in both monocytes and lymphocytes via
metabolic regulation. This data additionally raises the question of whether or not
TIPE2 could be one of the key linkages between diabetes/obesity and
inflammation, since it provides a direct connection between inflammation and the
mTOR nutrient sensing pathway.
In Chapter 5 the effect of TIPE2 on negatively regulating both the RGL1
and mTOR is investigated by looking into the role TIPE2 plays in inducing cell
death.

Here we see that overexpression of TIPE2 induces cell death, while

coexpressing RGL, mTOR, or parts of the mTOR pathway rescue from death.
We also discovered that TIPE2 is likely activated by p70S6K, since the presence
of S6K increases TIPE2 induced cell death. Finally we see that TIPE2 alongside
GBL and RGL creates a maximal amount of cell death, likely hinting at the role of
TIPE2 in providing a linkage between these two pathways.
Overall, the findings presented in this doctoral work will help to better
understand the functioning of TIPE2, and how it intersects with various signaling
pathways within the cell.

This knowledge may serve to provide valuable

treatments and therapeutics for an extraordinarily wide array of diseases, from
chronic inflammatory disease to diabetes to obesity to cancer. Each of these
diseases carries the common thread of being associated with a dysregulation of
inflammation.

Likewise, TIPE2 has now been established to not only have

connections to inflammation, but to each of these diseases.

With hope this
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information will be able to help solve the problems currently posed by each of
these diseases… and more.
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Figure 1.1 Overview of GTPase signaling. Small GTPase is “off” when bound to
GDP; a GEF then removes GDP and allows GTP to bind to the GTPase, turning it “on”.
All GTPases can eventually hydrolyze GTP to GDP and turn themselves off, though
GAPs rapidly accelerate this process.
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Figure 1.2: The Ras Superfamily. The Ras superfamily is broken down into 6 families,
each listed with their primary functions.
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Figure 1.3. Overview of Ras Signaling. Ras signaling pathway is highlighted in Red.
The Ral signaling segment of the Ras pathway is additionally marked in Green.
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Figure 1.4 Outline of Research Goals
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Chapter 2
TIPE2 Regulation
by NF-KB
Work from this chapter is from:
Gus-Brautbar, Y., Johnson, D., Zhang, L., Sun,H., Wang, P., Zhang, S., Zhang,
L., and Chen, Y.H. (2012). The anti-inflammatory TIPE2 is an inhibitor of
the oncogenic Ras. Molecular Cell 45, 610–618.
Wang, Z., Fayngerts, S., Wang, P., Sun, H., Johnson, D.S., Ruan, Q., Guo, W.,
and Chen, Y.H. (2012). TIPE2 protein serves as a negative regulator of
phagocytosis and oxidative burst during infection. Proceedings of the
National Academy of Sciences of the United States of America 109,
15413–15418.
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Abstract
TIPE2 is a known regulator of inflammation, yet little is known about how
TIPE2 responds to inflammatory signals.

Here we investigated the effect of

stimulating macrophages with various TLR ligands on TIPE2 expression. TIPE2
is rapidly and specifically downregulated by all TLR ligands tested. The same
downregulation occurred in T cells stimulated with PMA and Ionomycin. This
downregulation was further assessed with an inhibitor analysis and was found to
be dependent upon both active transcription, and upon active NF-KB activity.
Neither translation nor JNK activity appear to play a role in the downregulation of
TIPE2. These data suggest that an NF-KB induced miRNA may be responsible
for downregulating TIPE2 upon the presence of inflammatory signals.

We

additionally show that TIPE2 is ubiquitylated for its degradation, and that TIPE2
interacts with the BTRCP E3 Ligase, which may be the ligase that regulates the
TIPE2 protein levels.
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Introduction
The first step towards understanding a new molecule is to deduce how it is
regulated. By understanding the “how” and “why” of a new molecule’s regulation,
we can begin to gain insight into both its function, and understand the magnitude
of its importance. While it has been established that TIPE2 is a regulator of
inflammation via work with TIPE2 -/- knockout mice and tissues as well as in vitro
work, how TIPE2 was connected to inflammation had remained a mystery.
In the cell there are generally two primary forms of regulation; nucleic acid
regulation and protein regulation.

Nucleic acid regulation occurs when the

transcription of DNA into mRNA, or the mRNA itself is altered (Figure 2.1). This
form of regulation typically occurs via one of two mechanisms; direct action of
transcription factors on genomic DNA, or action of microRNAs towards target
mRNA sequences.

Transcription factors are proteins which enter into the

nucleus of a cell and bind to a specific DNA sequence. The transcription factor
then either recruits cellular machinery to begin transcription of the target gene
into mRNA, or it recruits cellular machinery to shut down transcription of the
target gene into mRNA.

Which effect occurs depends upon the particular

transcription factor(s), DNA sequences, and cellular conditions involved. Micro
RNAs (abbreviated miRNA) are small regulatory RNAs that are encoded in the
genomes of eukaryotic cells. miRNAs will bind to one or more specific target
mRNAs, typically on the 3‘ UTR, and are able to affect mRNA function via
marking them for destruction or in negatively regulating the translation of the
target mRNA.
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Protein regulation occurs when cellular conditions or signaling events
dictate a change be made to an already existing protein (Figure 2.2). Certain
changes, such as lipid modifications like palmitoylation, farnesylation, or
geranylgeranylation usually assist a protein in anchoring to the plasma
membrane or another vesicular structure; this anchoring both alters localization
of the modified protein and drastically extends its half-life. Other modifications
such as poly ubiquitylation on certain lysine residues, marks the protein for
destruction by the proteasome – the protein garbage disposal unit of the cell.
While ubiquitylation occurs at a steady state rate to destroy old proteins within
the cell, anything that increases the rate of ubiquitylation will decrease the halflife of the target substantially. Phosphorylation is another common method of
regulating proteins.

Phosphorylation typically activates whichever protein is

phosphorylated by altering its conformation, or by altering which other proteins it
interacts with. However, depending upon the cellular conditions, and the specific
phosphorylation target, phosphorylation can have many other diverse effects.
Nuclear Factor Kappa B (NF-B) is a term for a well-known family of
transcription factors (for review see Pasparakis 2009 and Perkins 2012). These
transcription factors exist as dimers of five possible subunits; p65, cREL, p50,
p52, RelB. NF-KB has been heavily studied in the field of immunology, and most
inflammatory signals activate NF-KB activity.

Thus, NF-KB provides one

possible method by which inflammatory signals are capable of signaling to the
cell that inflammatory regulators, such as TIPE2, need to be turned on or turned
off.
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Materials & Methods
Cell Lines and Animals
Raw 264.7 and EL4 cells were purchased from ATCC and grown in DMEM
supplemented with 10% FBS, penicillin and streptomycin. C57BL/6J (B6) mice
that carry a Tipe2 gene null mutation were generated by backcrossing Tipe2-/129 mice (Sun et al., 2008) to B6 mice for 12 generations.
Bone marrow deried macrophages were isolated from mouse femurs and were
cultured for seven days in DMEM supplemented with 10% FCS, 1%
Penicillin/streptomycin, 1% glutamine, and 30% L-929 cell culture supernatant.
Following culturing cells were washed with cold PBS and rested overnight in
complete DMEM before being lysed for testing.

Bone marrow derived

macrophages were >95% cd11b+ and F4/80+ as determined by flow cytometry.
Inhibitors:
Bay-11-7082 in solution was purchased from emdmillipore (part# 196870-10MG).
and was used at a concentration of 100 uM.
Actinomycin D was purchased from Sigma (part# A1410) and was used at a
concentration of 1 ug/mL.
Cycloheximide was purchased from Sigma (part# 01810-5g) and was used at a
concentration of 5 ug/ml.
Treatment:
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TLR agonists were purchased from invivogen part# tlrl-kit1mw and were used per
manufacturer’s instructions for maximum stimulation.
Quantitative RT-PCR
Total RNA was extracted with RNEasy (Qiagen, Valencia, CA) according
to the manufacturer's instructions. Reverse transcription was performed with
oligo dT primers. Real-time PCR was carried out in an Applied Biosystems 7500
system with Power SYBR Green PCR Master Mix (Applied Biosystems) and with
specific quantitect primers (Qiagen, Valencia CA) for mouse GAPDH and TIPE2.
Relative levels of gene expression were determined by normalizing TIPE2 levels
to the endogenous control gene GAPDH.

Relative TIPE2 levels were set to a

value of 1 at time point zero, subsequent time points compare relative TIPE2
levels to this initial level.
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Results
TLR Treatment
In order to assess how TIPE2 was affected by inflammatory signals, RAW
264.7 macrophages were treated with LPS over an eight hour time course
(Figure 2.4A), and the level of TIPE2 mRNA was measured at various time points
throughout the time course via real time PCR. TIPE2 expression was reduced to
approximately 35% of initial levels by 2.5 – 3 hours. Signal levels returned to
normal levels within 8 hours. To test whether other TLRs were involved in this
signaling process TLR3, TLR7, and TLR9 were tested by stimulating cells with
polyI:C, flagellin, and cpg respectively. Each of these TLR ligands showed a
similar effect to that of LPS. To ensure that this phenomenon was not limited
only to RAW cells, bone marrow derived macrophages were subjected to similar
treatments, and EL4 T Cells were subjected to treatment with PMA and
Ionomycin (Figure 2.4B). PMA/Ionomycin of EL4 T cells showed a similar pattern
of TIPE2 reduction by 2.5-3 hours, and a slow return to normal levels by 8 hours
(Figure 2.4B). Bone marrow derived macrophages showed a similar pattern of
reduced expression, but expression stayed reduced out to at least 24 hours.
Protein levels of bone marrow derived macrophages were also checked, to
ensure that changes in message levels correlated with changes in protein levels
(Figure 2.5).
Inhibitor Analysis

29 | P a g e

To test whether TLR signaling was inducing production of a protein that
was destroying TIPE2 mRNA or preventing its transcription, cells were pretreated
with cycloheximide to inhibit translation before TLR agonist treatment (Figure
2.6).

Pre-treatment with cylclohexamide had no effect on the TLR mediated

reduction of TIPE2 message levels. Since preventing protein production did not
stop the reduction in TIPE2 message levels, we next pre-treated cells with
actinomycin D in order to prevent transcription (Figure 2.6).

This treatment

prevented the TLR mediated reduction in TIPE2 message levels, implying that
fresh transcription was required for the reduction in TIPE2 expression. Finally in
order to identify the transcription factors responsible for inducing the
transcriptional event that was reducing TIPE2 expression, both Sp100125 and
Bay 11-7082 were used to pretreat cells (Figure 2.7). These compounds inhibit
JNK and NF-KB respectively.

While JNK inhibition had no effect on TIPE2

expression, inhibition of NF-KB by Bay 11-7082 prevented the TLR driven
reduction in TIPE2 expression.
Protein Regulation
In order to assess the effect of regulation on the TIPE2 protein, we
performed a pulse chase assay in which Raw 264.7 cells were treated with
cycloheximide in order to stop fresh translation, followed by either LPS or vehicle
administration. LPS treated Raw cells showed a significantly reduced TIPE2
protein half-life compared to vehicle treated controls (Figure 2.8B). In order to
identify the likely method of regulation a ubiquitin ligase assay was performed
(Figure 2.8A), which shows that TIPE2 is able to be ubiquitylated and thus may
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be marked for degradation by the proteasome. Data discussed in Chapter 3
(figure 3.11c) indicates that inhibition of the proteasome can restore repressed
TIPE2 protein expression, further lending support to the idea that TIPE2 is able
to be regulated by the proteasome.
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Discussion
Understanding the cellular events that regulate TIPE2 expression is
important

to

gain

insight

into

its

function

as

a

modulator

of

inflammation. Expression of TIPE2 is heavily downregulated by treatment with
poly I:C, LPS, Flagellin, and imidazoquinoline; agonists for tlrs 3,4,5, and 7
respectively. This group of TLR ligands signal via both MyD88 and TRAM/TRIF
signaling, indicating that that multiple intracellular signaling complexes have been
activated, leading to downstream activation of the NF-KB, AP-1, and IRF
transcription factor complexes (for review see O’Neill 2007). This effect is
phenocopied by treatment of T Cells with PMA/Ionomcyin, which activates many
of the same downstream transcription factors, therefore activation of one or more
of these pathways is responsible for the loss of TIPE2 message and therefore
the loss of TIPE2 protein.
In order to narrow down the molecule(s) responsible for this regulation,
RAW 264.7 macrophages and EL4 T Cells were pre-treated with either
SP600125, an inhibitor of JNKs 1,2, and 3, or Bay 11-7082, an inhibitor of IKBa,
which effectively inhibits NF-KB activation. Following pre-treatment with inhibitor
cells were either activated with TLR ligands (RAW 264.7 cells) or PMA/Ionomycin
(EL4 T Cells) in order to assess the importance of the targeted pathways on
TIPE2 message destruction. While SP600125 pre-treatment had no effect on
TIPE2 message levels, pre-treatment with Bay 11-7082 completely prevented the
TLR and PMA/Ionomycin mediated reduction in TIPE2 levels, indicating that NFKB activity was required for the cellular activation ligands to transmit the signal
that negatively regulate TIPE2 mRNA levels.
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Having identified NF-KB as the relevant transcription factor involved, it
was now necessary to identify how NF-KB was regulating TIPE2 message levels.
In order to identify the method of TIPE2 down-regulation, both RAW 264.7
macrophages and EL4 T Cells were pre-treated with inhibitors of translation
(cycloheximide), or transcription (actinomycin D) before stimulating them with
either TLR ligands or PMA and Ionomycin. Cycloheximide had no effect on the
TLR or PMA/Ionomycin mediated reduction in TIPE2 mRNA levels, indicating
that fresh translation of some RNA editing enzyme or transcriptional repressor
was not responsible for the loss of TIPE2 message. Actinomycin D however
completely ablated the activation induced reduction in TIPE2 message levels,
oddly indicating that fresh transcription was required to reduce TIPE2 mRNA
levels.
Since the down-regulation of TIPE2 has a dependence upon fresh
transcription, but not fresh translation, and a dependence upon NF-KB activity,
we conclude that during periods of acute inflammation TIPE2 is down-regulated
by an NF-KB targeted miRNA. Preliminary evidence (Chen Lab unpublished
data) indicates that the miRNA of interest is mir21.
Interestingly when primary cells were used instead of cell lines, the loss of
TIPE2 was not reversed even after 48 hours (Chen Lab unpublished data). This
implies that in vivo TIPE2 expression likely remains reduced for a fairly significant
amount of time following an infectious challenge, in order to allow the immune
system to have time to mount a full and complete defense. We have additionally
identified that TIPE2 is degraded at the protein level in response to LPS
stimulation, and that this degradation is likely due to ubiquitylation and
subsequent degradation by the proteasome. Additional work will be required in
order to deduce which E3 ligase is involved in this process.
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Figure 2.1 Mechanism of Nucleic Acid Regulation. Nucleic acids are regulated via two
key mechanisms. The first involves a transcription factor entering the nucleus and
binding directly to genomic DNA. The transcription factor then acts as a platform which
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either recruits other molecules which either activate or inhibit transcription. The second
mode of regulation is via microRNAs (miRNAs). miRNAs are small strands of RNA,
averaging about 22 nucleotides in length. They bind to complementary messenger RNAs
(mRNA) and typically either cause the mRNA to be destroyed, or interfere with its ability
to be translated.
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Figure 2.2 Mechanism of Protein Regulation. Some of the common modifications which
regulate protein function and stability: Ubiquitylation typically marks proteins for
destruction by the proteasome. Phosphorylation typically switches proteins into an active
conformation. Lipid modifications typically contribute to protein stability by allowing
them to associate with membranes or vesicular structures.
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Figure 2.2
TLR1 Binds Triacyl
lipopeptides
TLR4 Detects LPS
from the cell wall
of Gram negative
bacteria

TLR3 detects
double stranded
RNA from viruses,
poly I:C

TLR2 Binds multiple
bacterial lipid proteins
2

4 4
1

TLR7 and TLR8 recognizes
viral single stranded RNA,
imidazoquinoline

TLR5 detects
bacterial flagellin
protein

5
3

7

8

Intracellular
Endosome

9

TLR 9 binds to
unmethylated
CPGs
6

TLR6 binds
Diacyl
Lipopeptides

Figure 2.3 Overview of TLRs on Macrophages. TLRs (toll like receptors) are pattern
recognition receptors which bind to various microbial products and alert the cell to the
presence of a microbe in or around the cell.
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A

B

Figure 2.4 Reduction in TIPE2 expression Following Activation with LPS or
PMA/Ionomycin. A.) Raw 264.7 macrophages were treated with 100 ng/ml LPS for 8
hours and Cells were lysed and RNA extracted at various timepoints along the time
course, and levels of TIPE2 mRNA were measured via qPCR. B.) EL4 T Cells were
treated with PMA/Ionomycin for 8 hours and cells were lysed and RNA extracted at
various timepoints along the time course, and levels of TIPE2 mRNA were measured via
qPCR.
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Figure 2.5 TIPE2 Protein level in primary cells following LPS Stimulation.

Bone

marrow derived macrophages were treated with 100 ng/ml of LPS and were analyzed by
Western Blot.
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Figure 2.6 Cell Process Inhibitor Treatments of Stimulated Cells.

Raw 264.7

macrophages were treated with 100 ng/ml LPS for 3 hours, and were treated with
cycloheximide to inhibit fresh protein translation, or were treated with Actinomycin D in
order to inhibit fresh transcription.
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Figure 2.7 Cell pathway inhibitor treatments of stimulated cells. Raw 264.7
macrophages were treated with sp600125 in order to inhibit JNK Signaling, or were
treated with Bay 11-7082 to inhibit NF-KB signaling.
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A

B

Figure 2.8 TIPE2 is Ubiquitylated and Regulated at the Protein Level. A.) Ubiquitination
of TIPE2. 293T cells were transfected with either TIPE2-Flag or p50-Flag as a positive
control.

These cells were treated with MG132 (10 um), the lysates were

immunoprecipitated with an anti flag antibody, and ubiquitination status was examined as
described in Carmody et al., 2007). B.) TIPE2 protein half-life is reduced by LPS
treatment. Raw 264.7 cells were treated with LPS (100 ng/ml) and cycloheximide (100
um) for the indicated times. Cells were lysed and endogenous TIPE2 protein levels were
examined using anti-TIPE2 antibody.
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Chapter 3
TIPE2 Binds to and
Inhibits RGL1
Work from this chapter is from: *Gus-Brautbar, Y., *Johnson, D., Zhang, L., Sun,
H., Wang, P., Zhang, S., Zhang, L., and Chen, Y.H. (2012). The antiinflammatory TIPE2 is an inhibitor of the oncogenic Ras. Molecular Cell 45, 610–
618.

*These Authors Contributed Equally To This Work
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Abstract
TIPE2 has been established as a regulator of immunity and inflammation,
yet the mechanism(s) by which this occurs have remained elusive. Here we
report that TIPE2 interacts with the RalGDS family of GEFs, and by doing so
inhibits their activity. This inhibition affects both their scaffolding activity for AKT
and PDK1, as well as their GEF activity towards the Ral small GTPases.
Inhibition of the Ral proteins leads to a plethora of cellular effects, including
inhibition of the exocyst complex, inhibition of NF-KB, as well as impacts cell
survival, wound healing, migration, and anchorage independent growth.
Expression of TIPE2 in tumor cells delays tumor onset, and tumor onset can only
proceed following the silencing of the TIPE2 protein expressed in these cells.
Finally TIPE2 is highly downregulated in human hepatocellular carcinoma,
indicating that TIPE2 may be a future therapeutic target or provide a diagnostic
indicator for human cancer.
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Introduction
Ras is a major regulator of cell survival, proliferation, migration, and
transformation. Alongside phosphatidylinositol (PI) 3 kinase and Raf1, Ral
guanine nucleotide dissociation stimulator (RalGDS) family makes up the third
arm of Ras effectors.

The RalGDS family members are Guanine nucleotide

Exchange Factors (GEFs) for the small GTPases RalA and RalB, switching
GDP-bound inactive to GTP-bound active form of Ral (Ferro and Trabalzini,
2010; Spaargaren and Bischoff, 1994). A subset of the RalGEFs, including
RalGDS, RGL and RGL2/Rlf, are direct effectors for activated Ras, which binds
their C-termini and enhances their GEF activity towards Ral (White et al., 1996;
Wolthuis et al., 1996). The RalGEF pathway plays a prominent role in mediating
Ras-induced

oncogenic

transformation

in

humans.

RalGDS

deficiency

suppresses Ras-mediated tumor formation (Gonzalez-Garcia et al., 2005). In
rodent fibroblasts, the RalGEF effector pathway cooperates with the MAPK
pathway to promote transformation and metastasis (Ward et al., 2001; White et
al., 1996). In humans, the activation of this pathway is essential for
transformation in a variety of cell types (Hamad et al., 2002; Rangarajan et al.,
2004).
The RalGDS transforming ability is mediated by the active RalA and RalB.
Active Rals regulate various biological processes including cell proliferation,
motility, endo- and exocytosis, and cellular architecture (Feig, 2003). RalA and
RalB have distinct and sometimes conflicting roles, during oncogenic
transformation despite their high sequence identity (over 80%). RalA, but not
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RalB, is critical for RalGDS-mediated transformation, and RalA is more potent
than RalB in promoting anchorage-independent growth and targeted delivery of
proteins to basolateral membrane in epithelial cells. On the other hand, RalB is
more effective than RalA in promoting cell migration and activation of TBK1, and
in suppressing apoptosis and promoting metastasis (Chien et al., 2006; Chien
and White, 2003; Lim et al., 2005; Lim et al., 2006). Constitutively active forms of
RalA and RalB can transform human cell lines (Lim et al., 2005). Both RalA and
RalB are activated in human malignancies such as bladder, pancreas and colon
cancers, and they collaborate to promote and maintain oncogenic transformation
(Lim et al., 2006; Martin et al., 2011; Smith et al., 2007).
Recent studies suggest that the Ral effects on motility, secretion and cell
proliferation are largely mediated through the regulation of the exocyst complex.
This octameric complex regulates targeting and tethering of secretory vesicles to
specific plasma membrane domains, such as the leading edge of migrating cells
(Rosse et al., 2006; Spiczka and Yeaman, 2008). Two exocyst subunits, Sec5
and Exo84, are bona fide Ral effectors (Moskalenko et al., 2002), each of which
belongs to a different sub-complex. One sub-complex contains Exo84 and
Sec10, and is localized on the plasma membrane, whereas the other contains
Sec 5, 6, 8 subunits, and is located on secretory vesicles (He and Guo, 2009).
Active Ral promotes assembly of these two sub-complexes through dual subunit
interaction, leading to vesicle tethering to the plasma membrane (Jin et al., 2005;
Moskalenko et al., 2003). As the exocyst complex is being better understood, its
involvement in carcinogenesis has been brought to the forefront. Exocyst subunit
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interaction with active Ral is required for tumorigenesis of colorectal carcinoma,
progression of skin cancer, motility, anchorage-dependence, and survival of
transformed cells (Chien et al., 2006; Martin et al., 2011; Sowalsky et al., 2011).
An important function of the RalGDS family is to promote cell survival.
This may be mediated through both Ral GTPases (Chien and White, 2003) and
non-canonical activation of AKT (Hao et al., 2008). Canonical AKT activation
requires the generation of PIP3 by PI3K at the membrane. The PH domaincontaining proteins AKT and PDK1 bind these phoshoinositides, allowing AKT to
be phosphorylated by PDK1 (T308) and mTOR (S473). By contrast, in the noncanonical AKT activation pathway, RalGDS acts as a scaffold for PDK1 and
enhances its kinase activity, resulting in increased phosphorylation of AKT.
Active AKT phosphorylates a large number of substrates thereby protecting cells
from death (Sale and Sale, 2008). RalGDS-mediated AKT activation is
responsible for the proliferative effect of RalGDS in NIH3T3 cells (Hao et al.,
2008). In vivo, RalGDS regulates tumor growth by providing survival signals to
tumor cells, and consequently, in RalGDS-/- mice, apoptosis of carcinogeninduced papillomas is enhanced (Gonzalez-Garcia et al., 2005). Thus, the
regulation

of

transformation.

the

RalGEF

effector

pathway

is

key

to

Ras-mediated

Here, we describe an unexpected and previously unknown

connection between TIPE2 and the RalGDS family, and demonstrate its
relevance to cell survival, motility, and Ras-induced oncogenesis.
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Materials and Methods
Animals and human subjects
C57BL/6J (B6) mice that carry a Tipe2 gene null mutation were generated
by backcrossing Tipe2-/- 129 mice (Sun et al., 2008) to B6 mice for 12
generations.

Male

nude

mice

(nu/nu)

were

purchased

from

Jackson

Laboratories. Mice were housed in the University of Pennsylvania Animal Care
Facilities under pathogen-free conditions. All animal procedures used were preapproved by the Institutional Animal Care and Use Committee of the University of
Pennsylvania.
A total of 116 hepatocellular carcinoma specimens and 111 normal
adjacent hepatic tissue specimens were obtained from 116 patients aged
between 30 and 82 years who underwent operations at the Qilu Hospital of
Shandong University from January 2005 to October 2006. The pathological
diagnosis was made according to the current World Health Organization (WHO)
criteria for hepatocellular carcinoma. None of the patients studied had received
radiotherapy, chemotherapy, or adjuvant immunotherapy prior to surgery in order
to eliminate their effects on gene expression. All human procedures used were
pre-approved by the Institutional Review Board of the Shandong University.
Immunohistochemistry
Paraffin sections (4μm) were stained with rabbit anti-TIPE2 antibody (IgG)
overnight at 4°C. Secondary staining was performed with HRP-conjugated antirabbit IgG using a MaxVisionTM Kit and a DAB Peroxidase Substrate kit (Maixin
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Co., Fuzhou, China). The sections were counterstained with hematoxylin.
Unrelated rabbit IgG was used as a control for the primary antibody. All slides
were independently analyzed by two pathologists in a blinded manner, and
scored based on both staining intensity and the percentage of positive cells as
follows. Staining intensity: 0, no staining; 1, weak staining; 2, moderate staining;
3, strong staining. The percentage of positive cells: 0, <1%; 1, 1-33%; 2, 34-66%;
3, 67-100%. The two scores for each slide were then combined to produce a final
grade of TIPE2 expression: 0, total score = 0; 1+, total score = 1 to 2; 2+, total
score = 3 to 4; 3+, total score = 5 to 6. When there were discrepancies between
the two pathologists, the average score was used.
Cell lines and plasmids
The 293T, Raw 264.7, NIH 3T3, and Ras V12 NIH 3T3 cells were grown
in DMEM supplemented with 10% FBS, penicillin and streptomycin. To generate
stable cell lines, NIH 3T3 or Ras NIH3T3 cell lines (gift from Dr. Rotem Karni,
Hebrew University of Jerusalem) were infected with pBABE-puro retroviral vector
expressing TIPE2-Flag. Culture medium was replaced 24 hrs. after infection, and
after an additional 24 hrs., infected cells were selected with puromycin (1-1.5
g/ml) for 3 days. Expression of TIPE2-Flag was verified by Western blotting.
pRK5 and TIPE2-Flag-pRK5 were described previously (Sun et al., 2008). TIPE2
105-132 was generated from TIPE2 cDNA by PCR and cloned in-frame with a
C-terminal Flag tag into vector pRK5. pcDNA3-HA-AKT AAA was a gift from Dr.
Morris Birnbaum (University of Pennsylvania). Active AKT (pCDNA3-AKT T308D,
S473D), myr-PDK1 (pWZL Myr Flag PDK1), Active RalA (pBABE-RalAV23),
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Active RalB (pBABE-RalBQ72L) were purchased from Addgene. GFP-WT-RalA
and GFP-WT-RalB plasmids were a gift from Dr. Wei Guo (University of
Pennsylvania). Murine RGL cDNA (cDNA clone MGC:18430, IMAGE:4241244,
RGL-1 complete CDS) was obtained from ATCC. Full length RGL (amino acids
1-768) was generated from the cDNA clone by PCR, and cloned in-frame with a
C-terminal myc tag into vector pRK5 using BamHI-XhoI sites. N RGL (amino
acids 300-768),  RID RGL (amino acids 86-496), and RID RGL (amino acids
599-768) were generated from the cDNA clone by PCR, and cloned in-frame with
a C-terminal myc tag into vector pRK5 using BamHI-XhoI sites. TIPE2-FlagpBABE was generated by cloning PCR-amplified TIPE2-Flag fragment into
vector pBABE using BamHI/EcoRI sites.
Ral activity assay
The 293T cells, 2 x106 per 10-cm plate, were cultured for 24 hrs., and
then transfected with 10 g/plate pRK5 or TIPE2-Flag-pRK5 plasmid. Cells were
lysed at different time points after transfection with RAB buffer (Millipore)
supplemented with protease inhibitor cocktail tablet (Complete, Roche) and 1mM
PMSF. Protein concentration was determined by Bradford assay. 0.5 or 1 mg of
lysate was mixed with GST-RalBP1 agarose beads (Millipore) for 30 minutes at 4
0

C. After washing, protein on beads and in total cell lysates was subjected to

Western blot to determine the level of active RalA. The levels of active RalA in
Tipe2-/- or wild type macrophages were determined in the same manner.
Yeast-two-hybrid screen
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Yeast-two-hybrid screen for TIPE2-interacting proteins was carried out by
ProteinLinks Inc. (Pacadena, California, USA). A mouse splenic cDNA library
(1.7x107 cDNA clones) was used. 38 positive clones were initially found, and 24
of them were verified in a second screen. Of these, two clones encoded a murine
RGL (ref NM_016846.3, Mus Musculus Ral guanine nucleotide dissociation
stimulator-like 1) fragment, corresponding to amino acids 484-768.
Mass spectrometry
The 293 cells were transiently transfected with TIPE2-Flag or pRK5, and
in the mean time, Raw264.7 macrophages were plated in 15-cm plates. 24 hrs.
later, cells were lysed in CellLyticM buffer (Sigma) supplemented with protease
inhibitor

cocktail.

Lysates

were

cleared

by

centrifugation

and

protein

concentration was determined by Bradford assay. TIPE2-Flag or control lyastes
were immunoprecipitated using the anti-Flag-M2 affinity gel (Sigma), overnight at
4 0C. After three washes with CellLyticM buffer, pre-cleared Raw264.7 lysate was
added and incubated overnight, at 4 0C. Both TIPE2-Flag and pRK5 control were
then eluted using 3X Flag peptide (Sigma) and the eluates were separated on
10% SDS-PAGE gel. The gel was either stained with coomassie or silver, and
bands specific to the TIPE2-Flag lane were excised and sequenced.
F-actin determination
The total F-actin content in Raw 264.7 cells transiently transfected with
TIPE2 or pRK5, or in Tipe2-/- and wild type splenocytes, was measured as
follows. After cells were treated with LPS (200 ng/ml, Sigma), the reaction was
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stopped by addition of formaldehyde (to a final concentration of 3.7%) for 15 min
at room temperature. The fixed cells were permeabilized with ice-cold solubilizing
buffer (10 mM imidazole (pH 7.2), 40 mM KCl, 10 mM EGTA, 1% Triton X-100, 1
mM PMSF, 1 mM MgCl2, and protease inhibitor mixture tablet). F-actin was then
stained with NBD-phallacidin (Molecular Probes) for 2 hrs. at room temperature.
After two washes with PBS, F-actin-bound NBD-phallacidin was extracted with
methanol. Extracts were centrifuged and relative fluorescence was measured
using a fluorescent plate reader (Synergy 2, Biotek, USA) with excitation and
emission wavelengths set at 465 nm and 535 nm, respectively.
Wound healing assay
Tipe2-/- and wild type macrophages were grown to confluence in 10-cm
plates. Monolayers were wounded using a micropipette tip, and visualized using
a phase-contrast microscope. Images were acquired at various time points, and
the number of cells in the wounded area was counted using the ImageJ software.
Immunoprecipitation
Cells were lysed with CellLyticM buffer (Sigma) supplemented with
protease inhibitor (complete, Roche) and phosphatase inhibitor (PhosStop,
Roche) cocktail tablets. The lysates were cleared by centrifugation for 15 min,
and protein concentration was determined by Bradford assay. 40 l of 50%
protein G-sepharose beads was incubated for 1 hour at 4 0C, with one of the
following antibodies: myc (1:1000, cell signaling), Flag (2 g, Sigma), TIPE2
(1:500, Novus biological), and Sec5 (2 g, ProteinTech) antibodies, or IgG
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isotype controls (BD biosciences). The beads were incubated with 1 mg of total
protein from each lysate overnight at 4 0C, washed four times with CellLyticM
buffer, and boiled for 5 minutes in 40 l 2X SDS sample buffer. After SDS-PAGE
and transfer, the membranes were probed with antibodies against Flag (Flag-M2HRP, 1:1000, Sigma), Myc-HRP (1:1000, Cell signaling), Exo84 (Lifespan
Biosciences), Sec6 (1:1000 Assay Designs), TBK1 (1:1000, Cell Signaling),
PDK1 (1:1000, Cell Signaling), and RGL (1:500, abnova).
Immunoblotting
Cells were lysed in SDS and total protein concentration determined. 30 g
protein was loaded to each lane, and separated by SDS-PAGE. After transferring
to a nitrocellulose membrane, it was blocked with 5% milk in TBST and probed
with the following primary antibodies, overnight at 4 0C: Phospho–AKT (Serine
473, 1:1000, Cell signaling), total AKT (1:1000, Cell Signaling), Actin (1:1000,
Sigma), RalA (1:5000, BD Transduction Laboratories), Ras (1:500, abcam),
Phospho-IRF3 (1:1000, Cell Signaling), total IRF3 (1:1000, Cell Signaling)
antibodies. Detection was done using enhanced chemiluminescence of HRPconjugated secondary antibodies (anti-mouse or anti-rabbit IgG, 1:1000, GE
healthcare).
Quantitative RT-PCR
Total RNA was extracted with TRIzol (Invitrogen, Carlsbad, CA) according
to the manufacturer's instructions. Reverse transcription was performed with
oligo dT primers. Real-time PCR was carried out in an Applied Biosystems 7500
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system with Power SYBR Green PCR Master Mix (Applied Biosystems). Relative
levels of gene expression were determined with GAPDH as the control.
Anchorage-independent growth
Cells were cultured in duplicates in soft agar plates at 37 0C and 5% CO2.
After 10–14 days, colonies from ten different fields in each plate were counted,
and the average number of colonies per field was calculated. The colonies were
photographed using a GelDock camera.

Statistical analyses
Student’s t-test was used to evaluate the statistical significance of
differences in cell death, migration, and F-actin content. Mann-Whitney U test
was used to evaluate tumor onset, and Wilcoxon signed-rank test was used to
evaluate TIPE2 protein expression in human hepatic tissues.
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Results
TIPE2 prevents Ras from binding the Ras-interacting domain of RGL
The mechanisms of TIPE2 function are not clear. To address this issue,
we searched for binding partners of TIPE2 using a two-pronged approach.
Firstly, we conducted a yeast two-hybrid screen of a mouse splenic cDNA library
using TIPE2 as the bait, and secondly, we performed a large-scale
coimmunoprecipitation of TIPE2-binding proteins followed by mass spectrometry.
Among several clones isolated in the yeast-two hybrid screen, two were found to
encode the C-terminus region of the RGL. Consistent with this finding, mass
spectrometry results showed that TIPE2 pulled down with proteins of the RGLRal pathway. Together, these results suggested a role for TIPE2 in Rasmediated signaling. While other clones from the yeast-two hybrid screen
encoded proteins for Cytip, ORC1, and BRD2, these interactions were not
supported by co IP / tandem mass spectrometry data, and also were not able to
be endogenously immunocprecipated with TIPE2.
To establish whether endogenous TIPE2 interacts with RGL in
mammalian cells, we immunoprecipitated TIPE2 from the murine macrophage
cell line, Raw 264.7. We found that endogenous RGL co-precipitated with
endogenous TIPE2 (Figure 3.1), as did two other RalGEF family members,
RalGDS and RGL2. To map the region within RGL that is responsible for TIPE2
interaction, we cloned the murine full-length RGL (amino acids 1-768) or
truncated RGL (Figure 3.2B), in frame with a myc tag and co-transfected the fulllength or truncated RGL constructs into cells together with the TIPE2-Flag
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plasmid. TIPE2 pulled down with full-length RGL and the C-terminus of RGL.
However, TIPE2 did not pull down with a truncated RGL that lacked the Cterminal region (Figure 3.2A). These data indicate that TIPE2 binds to the Cterminus of RGL, which contains the Ras Interacting Domain (RID) (Murai et al.,
1997).
Active Ras binds the RID of RalGEFs and activates their GEF activity
(Murai et al., 1997; Urano et al., 1996). Our finding that TIPE2 binds the RID of
RGL (Figure 3.2A) suggests that in the presence of TIPE2, Ras would be unable
to bind RGL. We examined the presence of Ras in complex with RGL in 293T
cells transiently expressing full-length RGL and increasing amounts of TIPE2.
TIPE2 inhibited endogenous Ras from forming a complex with RGL, in a dosedependent manner (Figure 3.3). This indicates that TIPE2 can exclude active
Ras from binding to RGL.
TIPE2 inhibits RGL-induced activation of Ral
We then asked whether the outcome of TIPE2 binding to RGL could be
inhibition of RGL GEF activity towards its substrate Ral. In 293T cells transiently
overexpressing TIPE2, we detected more than 60 percent decrease in Ral GTP
level compared to the control (Figure 3.4A). Similar results were obtained in Raw
264.7 macrophages (data not shown). Active Ras levels were not affected by
overexpression of TIPE2. TIPE2 protein and mRNA levels were downregulated
in Raw 264.7 cells treated with LPS (Figure 2.4), and Ral activity was elevated
as a result of the treatment (Figure 3.4C) Moreover, TIPE2-deficient bone
marrow-derived macrophages showed a three-fold increase in active Ral level
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over wild type control cells (Figure 3.4B). These results indicate that TIPE2
serves as an inhibitor of RGL activity by blocking active Ras binding to RGL.
The RGL-PDK1 complex is induced by growth stimuli, and activated Ras
plays an important role in its formation. PDK1 relieves the intra-molecular
inhibition of the catalytic domain of RalGEFs by binding to its N-terminus, and
RalGEFs enhance PDK1 kinase activity preferentially towards AKT (Hao et al.,
2008)(Tian et al., 2002). Ras binding to RGL seems to be a necessary but
insufficient step in promoting RGL-PDK1 interaction, since a Ras mutant that
preferentially binds RalGEFs could not activate AKT under serum starvation
conditions (data not shown)(Tian et al., 2002). Expression of TIPE2 significantly
reduced PDK1 binding to RGL (Figure 3.5), implying that the disruption of Ras
binding to RGL may prevent RGL-PDK1 complex formation.
TIPE2 inhibits cell motility and exocyst complex assembly.
A hallmark of Ral function is its regulation of cell motility. Ral activation
promotes cellular protrusions and is essential for directional movement of cells
(Rosse et al., 2006; Sugihara et al., 2002). Active Ral mediates chemotaxis in
lymphocytes, plays a critical role in tumor metastasis, and contributes to
cytokinesis progression (Oxford et al., 2005). Ral mediates these effects by
regulating both actin dynamics and exocyst complex assembly. Actin
polymerization is essential for maintaining cell shape, internalization processes
(endocytosis and phagocytosis), and cell motility. We therefore examined the
effects of TIPE2 expression on actin polymerization. Polymerization of F-actin
can be induced by LPS stimulation in monocytes (Kong and Ge, 2008).
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Expression of TIPE2 in Raw 264.7 cells resulted in a significant decrease in the
total level of F-actin (Figure 3.6A). The F-actin polymerization rate in TIPE2transfected cells was also reduced. Conversely, in Tipe2-/- splenocytes, the rate
of F-actin polymerization was significantly enhanced compared to wild type cells
(Figure 3.6B). These results suggest that TIPE2 can impact both the rate of actin
polymerization and the total levels of F-actin in immune cells.
We next examined the exocyst subunit levels in Tipe2-/- splenocytes and
bone marrow-derived macrophages, and detected a significant increase in
exocyst subunits Sec 5, 6, 8 and 84 (Figure 3.7A). These results are consistent
with previous reports showing decreased absolute amounts of Sec5 and Sec6 in
RalA- or RalB-depleted rat kidney cells (Rosse et al., 2006). Next, we examined
whether TIPE2 impacts the formation of the exocyst complex, by measuring its
assembly from its two sub-complexes in wild type (WT) and Tipe2-/- cells. While
there was no difference in Sec5/Sec6 sub-complex assembly between Tipe2-/and WT cells, the association between Sec5 and Exo84 increased by about 3fold in Tipe2-/- cells (Figure 3.7A). Therefore, the Ral-regulated step of exocyst
assembly is defective in Tipe2-/- cells. Consistent with this observation, TIPE2
overexpression resulted in destabilization of the exocyst complex. In 293T cells
expressing TIPE2, the assembly of the sub-complex Sec5/Sec6 was unchanged,
while the assembly of Exo84 and Sec5 was markedly decreased (Figure 3.7B).
Ral depletion blocks exocyst complex formation at the leading edge of
migrating cells, and inhibits cell migration (Rosse et al., 2006; Spiczka and
Yeaman, 2008). We tested directional cell migration of Tipe2-/- macrophages in a
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wound-healing assay (Figure 3.8A). The “wound” was created in confluent Tipe2/-

and wild type cultures (time zero), and migration of cells into the gap was

monitored after 3 and 6 hrs. Wild type macrophages started moving into the
wound after 3 hrs., and by 6 hrs. the wound was still visible. However, Tipe2-/macrophages moved into the wound faster, and completely closed the gap by 6
hrs. Quantification of the number of cells that moved into the gap showed that
the rate of Tipe2-/- cell migration was 3-fold higher than that of the wild type
(Figure 3.8B). Moreover, Tipe2-/- macrophages that had moved into the wound
were elongated, and had increased number of cellular extensions, generally
assuming a “migratory” form. In contrast, wild type cells looked round, with
smaller number of extensions. Consistent with this finding, in vivo migration of
TIPE2 knockout leukocytes into skin air-pouches injected with the chemokine KC
(keratinocyte chemoattractant) was significantly enhanced as compared to wild
type controls (Sun 2012). The enhanced migratory phenotype of Tipe2-/- cells
could be mediated by irregularities of both actin dynamics and exocyst complex
assembly. These abnormalities may partly explain the increased inflammation in
Tipe2-/- mice.
Recently, it has been established that active RalB induces Sec5
dimerization and subsequent activation of TBK1 (Chien et al., 2006). This
pathway results in AKT activation, protects cancer cells from apoptosis, and is
required for mounting host defense responses. However, as described above,
the inhibition of Sec5-TBK1 interaction by TIPE2 does not appear to be a main
contributor to TIPE2-induced cell death. RalB and Sec5 are required for TLR3-
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induced

IRF3-dependent interferon-b production. We observed

reduced

interaction between Sec5 and TBK1 in TIPE2-overexpressing cells (Figure 3.7C),
and a reduction in phosphorylated IRF3. These results suggest that the
Ral/Sec5/TBK1 pathway is inhibited by TIPE2. It was shown previously that
TIPE2-deficient cells exhibit increased NF-kB activity. Therefore, TIPE2 may
regulate the NF-kB pathway through the Ral/Sec5/TBK1 axis.
TIPE2 inhibits tumorigenesis in vivo.
Activating mutations of Ras are found in ~30% of all malignant tumors.
The best-characterized Ras effector pathways are the Raf-MAPK and PI3K
pathways, and their importance in Ras-mediated oncogenesis has been
extensively studied. However, a growing body of evidence supports an important
role for the RalGDS family in Ras-induced growth and transformation of human
cells. To determine the potential roles of TIPE2 in tumorigenesis, the Rastransformed NIH 3T3 fibroblasts (Ras G12V) were used to stably express Flagtagged TIPE2. Expression of TIPE2 significantly reduced the growth of Ras 3T3
cells (Figure 3.9A). The effect was the most dramatic under low serum
conditions, where cells were more dependent on Ras for survival. Consistent with
these results, overexpression of TIPE2 in Ras 3T3 cells reduced colony
formation in soft agar (Figure 3.9B). Expression of TIPE2 in NIH 3T3 alone did
not result in colony formation. To test the effect of TIPE2 on tumor formation in
vivo, Ras 3T3 cell line stably expressing TIPE2 was injected into nude mice.
TIPE2 significantly delayed tumor onset in two independent experiments, in
comparison to control injections (Figure 3.10). NIH 3T3 or NIH 3T3 stably

60 | P a g e

expressing TIPE2 did not give rise to tumors. TIPE2 tumors, once formed, could
grow to the same weight as control, suggesting that TIPE2 tumors did not have a
growth disadvantage as compared to Ras 3T3 tumors. In addition, while Ral
activity was inhibited in the pre-injected cell lines, it was restored in isolated
tumor cells. This paradox could be explained if somehow the tumors in mice had
lost expression of TIPE2. Indeed, upon examining the tumors 14 and 22 days
after tumor cell inoculation, we could not detect any TIPE2 protein by
immunoblotting (Figure 3.11A). However, by quantitative RT-PCR, we could
clearly show that TIPE2 tumors expressed similar amounts of TIPE2 transcript
compared to TIPE2-expressing Ras 3T3 cells before injection (Figure 3.11B).
Therefore, it appears that TIPE2 downregulation in the tumor occurred at the
protein level. The half-life of TIPE2 protein is rather short, around 4 hrs. (Figure
2.8B), and the TIPE2 protein is heavily ubiquitylated in cells (Figure 2.8A). These
findings indicate that TIPE2 protein is likely regulated by ubiquitylation and
proteasomal degradation. Indeed, the reduced TIPE2 level in tumor cells could
be restored to that of pre-injected cells after treatment with the proteasome
inhibitor MG132 (Figure 3.11C). This indicates that TIPE2 degradation is
enhanced in the tumor cells. Therefore, cells that formed tumors were those that
had TIPE2 protein actively suppressed. These cells were likely present in the
pre-injected pool but were outnumbered by those that did express TIPE2.
However, once injected into the animal, cells that suppressed TIPE2 protein had
a significant survival advantage and were therefore positively selected. Although
TIPE2 tumors might have originated from fewer cells, as the delay in tumor onset
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suggests, they eventually reached the same size as the control tumors. Since
TIPE2 -/- mice do not develop spontaneous tumors, it is likely that loss of TIPE2
is a necessary, though not sufficient mutation for cancer progression. Treatment
of TIPE2 -/- mice with various carcinogens will help to better understand the
relationship between TIPE2 and cancer in the future. This unexpected result
suggests that mechanisms responsible for TIPE2 elimination may also result in
acquisition of a growth advantage over Ras3T3 control cells. These results point
to a role for TIPE2 as a novel tumor suppressor involved in carcinogenesis.
TIPE2 is markedly down-regulated in human hepatocellular carcinoma.
It was recently published that TIPE2 plays an important role in HBVinduced hepatitis (Xi et al., 2011). Chronic HBV infection is a major cause of
HCC and is prevalent among a large world population. Interestingly, RalGEF
plays a more prominent role in transforming human cells than murine cells
(Hamad et al., 2002). To test the possibility that TIPE2 regulates carcinogenesis
in humans, we examined the level of TIPE2 expression in the livers of 116
patients suffering from hepatocellular carcinoma. We found that TIPE2 was
expressed in normal hepatocytes adjacent to carcinoma cells. Remarkably,
~20% of carcinoma expressed little or no TIPE2 and the rest expressed
significantly lower levels as compared to adjacent hepatocytes (Figure 3.12 A-B).
TIPE2 re-expression in three cultured human HCC cell lines (HepG2, BEL7402,
and SMMC-7721) significantly reduced their growth and viability as measured by
flow cytometry and MTT [(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide] assay (unpublished data).

Consistent with the murine tumor data,
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down-regulation of TIPE2 occurred at the protein but not at mRNA level, because
RT-PCR

revealed

no

significant

difference

in

TIPE2

mRNA

between

hepatocellular carcinoma and its adjacent tissues (unpublished data). Thus,
development of human hepatocellular carcinoma is associated with the downregulation of TIPE2 protein.
In summary, we have discovered a novel mode of Ras regulation that is
carried out by TIPE2, a recently described anti-inflammatory protein containing a
novel fold. This mode of regulation is essential for maintaining an organism’s
immune homeostasis, because its defect leads to severe inflammation and
cancer progression. This finding provides a novel molecular bridge between
inflammation and cancer, a connection widely recognized, but poorly understood
(Karin and Greten, 2005). Thus, inflammation may cause cancer by inhibiting the
expression of the tumor suppressor TIPE2 (Figure 3.13), in addition to activating
the oncogenic NF-kB (Karin and Greten, 2005). Due to its diverse effects on cell
survival and motility, the Ras inhibitor TIPE2 represents an attractive new drug
target for neoplastic and inflammatory diseases.
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Figure 3.1 TIPE2 and RGL1 Co Immunoprecipitation. Raw 264.7 cells were lysed and
immunoprecipitated with anti TIPE2 antibody (Novus Bio). IPs were then analyzed by
SDS-PAGE and western blot.
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A

B

Figure 3.2 TIPE2 interacts with the “Ras interaction domain” of RGL. A series of RGL
truncations were created deleting various important domains of the molecule. These
mutants

were

then

coexpressed

alongside

flag

tagged

TIPE2

and

co-

immunoprecipitations were performed. The only mutant that TIPE2 could not coIP with
was the mutant lacking the RID of RGL.
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Figure 3.3 TIPE2 Displaces Ras from RGL. Myc tagged RGL1 was co expressed with
increasing amounts of flag tagged TIPE2. RGL1 was then IP’d using an anti myc
antibody and the amount of Ras bound to RGL was measured via western blot.
Increasing amounts of TIPE2 lead to decreased Ras/RGL1 interaction
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A

B

C
Figure 3.4 TIPE2 Regulates Ral Activity. A.) 293T cells were transfected with Flag
tagged TIPE2, and GTP bound Ral was measured. TIPE2 Reduces the amount of GTP
bound Ral. B.) TIPE2 -/- bone marrow derived macrophages were lysed and active Ral
levels were compared to those of w.t. bone marrow derived macrophages. TIPE2 -/67 | P a g e

macrophages possess more GTP bound RalA than their wild type counterparts. C.)
RAW 264.7 macrophages were stimulated with LPS and active Ral levels were assayed
via a Ral activity assay and western blot.
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Figure 3.5 TIPE2 Displaces PDK1 From RGL1. Myc tagged RGL1 was co expressed
with increasing amounts of flag tagged TIPE2. RGL1 was then IP’d using an anti myc
antibody and the amount of PDK1 bound to RGL was measured via western blot.
Increasing amounts of TIPE2 lead to decreased PDK1/RGL1 interaction.
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Figure 3.6 Effect of TIPE2 on Actin Polymerization. A.) Raw 264.7 macrophages
transfected with either flag tagged TIPE2 or empty plasmid (pRK5) following LPS
stimulation (200ng/ml) for the indicated times.

F (Filamentous) actin levels were

determined as described in methods on pages 47-48. The value of the TIPE2 group at
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time point zero was set to a value of 1. Results are means +/- SEM and were pooled from
three independent experiments (n=12). *p<0.05; ** p<0.01.

B.) F actin levels were

measured in splenocytes from TIPE2 -/- animals or their wild type counterparts at the
indicated timepoints following 200 ng/ml LPS stimulation as described in methods on
pages 47-48. The value at time point zero was set to a value of 1. Results are means +/SEM and were pooled from three independent experiments (n=6). * p<0.05; ** p<0.02.
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A

B

Figure 3.7

TIPE2 induces a dysregulation of the Exocyst Complex.

A.)

Co

immunoprecipitations were carried out for Sec5 and Exo84 and Sec6 in both knockout
and wild type bone marrow derived macrophages. Loss of TIPE2 increased the strength
of the Sec5/Exo84 interaction. B.) Flag tagged TIPE2 was transfected in increasing
amounts in 293T cells and Sec5 was co immunoprecipitated with Sec6 and Exo84.
Increasing amounts of TIPE reduce the Sec5/Exo84 interaction (Ral regulated step) but
have no effect on the Sec5/Sec6 interaction.
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A

B

Figure 3.8 Loss of TIPE2 Increases Macrophage Movement. TIPE2 -/- and wt bone
marrow derived macrophages were grown on polystyrene dishes.

A “wound” was

created in the monolayer with a sterile pipette tip and the resulting movement of the
macrophages into the wound was followed by microscopy.
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Figure 3.9 TIPE2 Affects Growth and Colony Formation in Soft Agar. A.) TIPE2 was
stably expressed via viral transduction into NIH-3T3 cells and cell growth was
monitored.

TIPE2 significantly reduced cell growth.

B.)

NIH-3T3 cells were

transformed with TIPE2 and ability to form colonies in soft agar was compared with
control NIH-3T3 cells. TIPE2 significantly reduced colony formation in soft agar.
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Figure 3.10 TIPE2 delays tumorigenesis in nude mice. Ras-transformed NIH 3T3
cells that did or did not express TIPE2 were injected subcutaneously into the rear
flanks of nude mice (2 x106 cells/injection, n = 3), and tumor formation was
monitored daily. All sites injected with Ras-transformed NIH 3T3 cells eventually
developed tumors, whereas control NIH 3T3 or NIH 3T3-TIPE2 cell lines did not
give rise to tumors during the course of this study. Data shown are percent of
tumors formed and are representative of two independent experiments. The
differences between the two groups are statistically significant (p = 0.014).
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C
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Figure 3.11 Tumors Silence TIPE2 in order to grow. A.) TIPE2 protein levels were
measured in Ras transformed NIH-3T3 cells expressing TIPE2 before injection into Nude
mice, and then at 14 and 22 days following tumor onset. TIPE2 was not detectable in
tumors. B.) TIPE2 message levels were checked in pre injection cells as well as tumors,
and TIPE2 RNA levels were not changed between samples. C.) Reconstituted tumors
were treated with MG132 in order to inhibit the proteasome to check the effect on TIPE2
levels. Inhibition of the proteasome allowed TIPE2 levels to rise even beyond those in
the pre injection cell lines.
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C

Figure 3.12 Amount of TIPE2 expression in human hepatocellular carcinoma in. A.)
Tumor tissue and B.) control hepatic tissue adjacent to the tumor from the same patient
was determined by immunohistochemistry as described in materials&methods beginning
on page 43.

TIP2 positive cells are stained in brown, magnification x400.

C.)

Quantificatino of the TIPE2 signal from 116 patients was performed as described in
methods beginning on page 43. The differences between the two groups are statistically
significant (p<.001).
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Figure 3.13 Putative TIPE2 and RGL1 Mechanism.
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Chapter 4
TIPE2 and mTOR
Inhibition

The work in this chapter is unpublished data, and is intended to be published in the near
future.
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Abstract
mTOR is a serine/threonine kinase that plays a central role in responding
to nutrient and environmental cues.

mTOR interprets these cues, and dictates

to the cell whether anabolic or catabolic programming should be initiated, as well
as a host of other important cellular changes. TIPE2 negatively regulates the
mTOR pathway, resulting in a marked change in primary mTOR effectors.
Overexpression of TIPE2 induces a marked down-regulation of the Rictor
component of mTORC2, while TIPE2 -/- cells show an increased amount of
Rictor. TIPE2 interacts with the GBL common subunit of both the mTORC1 and
mTORC2 complexes, and this interaction may be responsible for the loss of
Rictor induced by TIPE2, which in turn likely explains the marked reduction in
downstream mTOR signaling.
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Introduction
mTOR (mechanistic Target Of Rapamycin, also referred to as the
mammalian Target Of Rapamycin) is a serine/threonine kinase that plays the
predominant role in interpreting environmental signals to control cell growth and
protein synthesis, cell survival, cell proliferation, and cell motility (Zoncu 2011).
This kinase was originally identified as the target of the immunosuppressive
macrolide rapamycin, and his since been recognized as an extraordinarily
important molecule in regulating proper cell function. Due to its central function
in regulating so many different processes mTOR dysregulation has been linked
to numerous disease states, including obesity (Um 2004), cancer (Aoki 2001,
Shah 2001, Podsypanina 2001), type 2 diabetes, neurodegeneration (Chong
2012), as well as others.
mTOR exerts its numerous biological functions via two protein complexes
named mTOR complex 1

(mTORC1) and mTOR complex 2 (mTORC2).

mTORC1 is composed of six protein subunits; mTOR, GBL, DEPTOR,

Raptor,

PRAS40, and the Tti/Tel2 complex. mTORC2 contains seven subunits; mTOR,
GBL, DEPTOR, Rictor, Sin1, Protor, and the Ti1/Tel2 complex.
mTORC1
mTORC1 functions as a cellular computer whose inputs are cellular
environmental conditions, and whose outputs are either growth and fresh protein
synthesis, or autophagy to conserve energy and materials (Zoncu 2001).
mTORC1 is capable of sensing the energy status of the cell via AMPK activity
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(Reviewed in Hardie 2007), the relative amount of amino acids present via
detecting the branched chain amino acid leucine (Sancak 2008,), the relative
amounts of lipids via binding phosphatidic acid (Fang 2001, Yoon 2011), it can
sense the presence of growth factors, the relative abundance of oxygen, as well
as cellular stress.

When mTORC1 has received signals acknowledging the

presence of oxygen, growth factors, energy, raw materials in the forms of lipids
and amino acids, as well as no negative stress signals, it will signal down to its
downstream effectors p70S6 Kinase (S6K) and eIF4E binding protein 1 (4EBP1)
to begin protein synthesis (Haghinghat 1995, Hara 1997, Holz 2005, Max Ma
2008, ). It will also inhibit the lipid inhibitor lipin 1 (Peterson 2011) as well as
signal to inhibit autophagy (Nobukini 2005). S6K is a kinase which performs
multiple functions to increase protein synthesis.

Its primary target is the S6

ribosomal protein, which it phosphorylates to induce protein synthesis at the
ribosome. S6K also increases translational initiation and elongation (Max Ma
2008), and can induce biogenesis of mRNA (Max Ma 2008) as well as
biogenesis of ribosomes (Mayer 2004, Jastrzebski 2007). 4EBP1 is an inhibitor
of the cap binding protein eIF4E (Pause 1994). eIF4E is a crucial part of the
eIF4F cap binding complex which is necessary in order to efficiently undergo
efficient cap dependent translation. mTORC1 can phosphorylate 4EBP1 which
marks it for degradation (Schalm 2003). Once 4EBP1 has been degraded eIF4E
is free to initiate cap dependent translation. Since protein synthesis is crucial for
the growth of a cell, mTORC1 is a master regulator of cellular growth.
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mTORC2
mTORC2 responds to growth factors, but not to nutrients in the way that
mTORC1 does. mTORC2 is the primary kinase that activates the AGC kinase
AKT (Sarbassov 2005), as well as the kinases SGK1 and PKC (Garcia 2008,
Facchinetti 2008). AKT is an extremely important survival signaling molecule
which promotes survival and reduces apoptois via multiple downstream effectors
such as the FoxO family of proteins (reviewed in Zhang 2011), which in turn can
affect the apoptosis modulators FasL and Bim, as well as the cell cycle activators
Cyclin D1 and D2. mTORC2 also plays a role in the organization of the actin
cytoskeleton (Sarbassov 2004).
mTOR in the Immune System
Due to the central position occupied by mTOR in regulating survival,
proliferation, and growth, it is no surprise that mTOR has been shown to have an
essential role within both the adaptive and innate immune system. Within the
adaptive immune system mTOR alters cell surface receptors that control T cell
trafficking (Finlay 2010). Inhibition of mTOR in activated CD8+ T cells increases
expression of CCR7 and CD62L (Sinclair 2008), increasing the trafficking of
these cells to secondary lymphoid organs (Sinclair 2008). Additionally there are
multiple threads of evidence indicating that mTOR modulates CD8+ memory T
Cell differentiation, inhibition of mTOR during the expansion phase of T Cell
response results in an increased number of memory CD8+ T cells (Rao 2010, Li
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2011).

Within CD4+ T cells mTOR plays crucial roles in the appropriate

differentiation into different CD4+ subsets. Loss of mTOR results in a loss of
differentiation into Th1, Th2, and Th17 subsets (Delgoffe 2009). When loss is
restricted to mTORC1 components Th1 and Th17 differentiation is impaired
(Delgoffe 2011), while loss of mTORC2 activity resulted in a failure to develop
properly differentiate into Th2 subsets (Delgoffe 2011).
mTOR also plays an important role in the proper operation of the innate
immune system. Animals expressing hypomorphic mTOR have smaller spleens
with fewer monocytes (Zhang 2011).

mTOR inhibition decreases generation of

human myeloid DCs (va de Laar 2010). Additionally DCs treated with rapamycin
have a poor ability to induce allogeneic t cell responses and instead induce Treg
differentiation (Haidinger 2010).

Moreover in various DC subsets rapamycin

treatment can impair type I interferon production (Cao 2008 and Colina 2008.),
and can also impair both pro- and anti-inflammatory cytokine production. Due to
its negative effect on autophagy, mTOR can reduce DC function by impairing DC
autophagy, a process important for proper antigen processing and presentation
(Lee 2007).

Paradoxically this indicates that depending upon the specific

conditions mTOR can either inhibit or enhance DC cell mediated T Cell
activation.
Inflammation and mTOR
Both diabetes and obesity are often linked to highly dysregulated mTOR
signaling.

Additionally “diabesity” as it is sometimes referred to is often
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described as a disease of inflammation, as both obesity and diabetes are highly
correlated with excess inflammation.

Attempting to infer causality between

inflammation and diabesity has proven to be difficult, and a better understanding
of how inflammatory signaling can intersect with the metabolic signaling involved
in diabetes and obesity is needed to understand this issue.
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Materials and Methods
Animals
C57BL/6J (B6) mice that carry a Tipe2 gene null mutation were generated
by backcrossing Tipe2-/- 129 mice (Sun et al., 2008) to B6 mice for 12
generations. Mice were housed in the University of Pennsylvania Animal Care
Facilities under pathogen-free conditions. All animal procedures used were preapproved by the Institutional Animal Care and Use Committee of the University of
Pennsylvania.
Cell lines and plasmids
HEK 293T cells were purchased from ATCC. Cells were grown in DMEM
supplemented with 10% FBS, penicillin and streptomycin. mTOR, Rictor, Raptor,
S6K1, and S6K2 plasmids were purchased from Addgene. Bone marrow was
removed from femur and was cultured for 7 days in DMEM supplemented with
10% FBS, penicillin and streptomycin and mCSF.
Immunoprecipitation
Cells were lysed with CellLyticM buffer (Sigma) supplemented with
protease inhibitor (complete, Roche) and phosphatase inhibitor (PhosStop,
Roche) cocktail tablets. The lysates were cleared by centrifugation for 15 min,
pre-cleared with 100 ul beads for 30 minutes, and protein concentration was
determined by Bradford assay. Antibody was added to 300 ug protein lysate and
rotated for 2 hours at 4C followed by addition of beads and rotation for an
additional 2 hours at 4C. Lysates were spun down, resuspended in Laemmli
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loading dye, and 30 ul of IP run through 4%-12% miniTGX gradient gels,
purchased from Biorad. After SDS-PAGE and transfer, the membranes were
probed with various antibodies.
Immunoblotting
Cells were lysed in SDS and total protein concentration determined. 30 g
protein was loaded to each lane, and separated by SDS-PAGE. After transferring
to a nitrocellulose membrane, it was blocked with 5% milk in TBST and probed
with the following primary antibody.
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Results and Discussion
TIPE2 has been reported to regulate the immune system, inflammation,
and survival, but the mechanisms by which it performs these functions are not
clear.

While attempting to identify survival pathways regulated by TIPE2, we

discovered that AKT phosphorylation is heavily dysregulated in bone marrow
derived macrophages isolated from TIPE2 knockout mice (Figure 4.2b). Loss of
TIPE2 leads to a marked increase in the amount of AKT phosphorylated at S473,
indicating increased survival signaling in these cells. This correlates with a prior
report of TIPE2 knockout cells being resistant to activation-induced-cell-death
(Sun 2008). Since loss of TIPE2 led to increased AKT phosphorylation, it raised
the question of whether additional TIPE2 could reduce AKT phosphorylation. To
test this effect the converse experiment was carried out and TIPE2 was
overexpressed

in

order

to

see

if

overexpression

could

inhibit

AKT

phosphorylation at S473. This overexpression did lead to a significant reduction
in phosphorylation of AKT (Figure 5.5b).
mTOR signals from two distinct complexes, mTORC1 and mTORC2
(Figure 4.1). While AKT is phosphorylated and activated by the mTORC2
complex, 4EBP1, S6K, and S6 are all downstream of the separate mTORC1
complex. Since AKT is a downstream effector of the mTORC2 complex, and
TIPE2 had such a potent effect on its signaling status, we next sought to
determine whether effectors downstream of mTORC1 were dysregulated by
TIPE2. Overexpression of TIPE2 led to large reductions in phosphorylated
4EBP1, p70S6K, and S6 (Figure 4.2 A,C), indicating that TIPE2 negatively
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regulates mTORC1 as well as mTORC2. When co-expressed with its binding
partner RGL, the TIPE2 mediated reduction in mTOR signaling is reduced
(Figure 4.2c), suggesting that TIPE2 has a separate and new binding partner via
which it is regulating mTOR signaling, and that overexpression of RGL is able to
compete away some of the TIPE2 from this binding partner.
Since it seemed likely that TIPE2 was regulating the mTORC1 and
mTORC2 complexes via a new interacting partner, a series of coimmunoprecipitations were performed between TIPE2 and members of the two
complexes. Since the two subunits that are

common to each complex are

mTOR and GBL, the effort was first focused on these two members. While
TIPE2 will coIP with mTOR itself, the interaction is quite weak and sporadic,
implying that the interaction is either transient or indirect.

When co-

immunoprecipitated with GBL however, TIPE2 showed a robust interaction, much
stronger than with mTOR (Figure 4.3). Since GBL binds directly to mTOR, it is
likely that any co-immunoprecipitation seen between TIPE2 and mTOR was
indirect and due to an interaction between TIPE2 and GBL, not an interaction
with mTOR itself.

Also coIPs were carried out between TIPE2 and the Raptor

and Rictor subunits of mTORC1 and mTORC2 respectively, and no interaction
was seen.
Next we sought to identify how an interaction between TIPE2 and GBL
could lead to such a marked reduction in mTOR downstream signaling. We
hypothesized that TIPE2 was binding and sequestering GBL, preventing it from
forming into functional mTORC1 and mTORC2 complexes, and since loss of
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GBL has been previously shown to lead to a loss of Rictor (Guertin 2006), the
effect of TIPE2 expression on Rictor was tested. Overexpression of TIPE2 led to
a severe reduction in Rictor levels present in cells, but not of either GBL or of
Raptor, implying that the reduction in protein was specific to just the Rictor
component of the mTORC2 complex (Figure 4.4b). Since overexpression of
TIPE2 leads to increased cell death (Chapter 5), it was necessary to ensure that
the loss of Rictor expression was a specific function of TIPE2, and not a nonspecific cell-death related effect. To test this, cells overexpressing Rictor with
and without TIPE2 were treated with etoposide to induce apoptosis, and only
those cells with TIPE2 present showed a reduction in Rictor protein
levels. Additionally TIPE2 knockout bone marrow derived macrophages were
compared to their wild type counterparts, and the knockout macrophages had
significantly more rictor present (Figure 4.4A).
TIPE2 interacts with the GBL constant subunit of both the mTORC1 and
mTORC2 complexes, effectively inhibiting their downstream signaling and
leading to a reduction in the amount of Rictor present in the cell. Rictor is the key
scaffold which maintains mTORC2 integrity, while Raptor is the key scaffold that
maintains mTORC1 integrity. While loss of GBL has been shown to correlate
with reduced levels of Rictor, its loss did not affect Raptor levels (Guertin
2006). In line with this a loss of GBL caused mTORC2 signaling to AKT to be
affected to a more significant degree than mTORC1 signaling to either p70S6K
or 4EBP1. This correlates strongly with what we see from TIPE2 overexpression
– a very strong reduction in phosphorylated AKT, a substrate of mTORC2, and a
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significant but less intense reduction in phosphorylated levels of p70S6K and
4EBP1, both substrates of mTORC1. It is both possible and likely that the effect
of TIPE2 on mTORC1 signaling is in actuality primarily occurring via its inhibition
of AKT via reduction in Rictor levels. AKT is capable of inhibiting the TSC1/2
complex, which in turn inhibits the activity of mTORC1. When AKT inhibits the
inhibitor, it allows mTORC1 to become active, phosphorylating its downstream
targets S6K and 4EBP1 (Vander Haar 2007, Sancak 2007).
The inhibitory effect of TIPE2 on mTOR signaling is particularly relevant
when

considering

TIPE2

through

the

prism

of

an

inflammatory

regulator. Animals expressing hypomorphic amounts of mTOR have smaller
spleens with fewer monocytes (Zhang 2011). TIPE2 knockout mice have an
opposite phenotype, having larger spleens (Sun 2008), with a larger percentage
of monocytes over wild type controls (Wang 2012). This is exactly what we
would expect if TIPE2 knockout cells are missing a crucial negative regulator of
mTOR signaling and thus mTOR is able to transduce a stronger signal than
would normally occur. Rapamycin treatment will inhibit mTOR activity, and
treatment of dendritic cells with rapamycin can impair type I interferon production
(Cao 2008, Colina 2008). In contrast, TIPE2 knockout dendritic cells produce
significantly more type I interferons (Sun 2012).

It is distinctly possible that

much of the ability for TIPE2 to regulate inflammation is due to its ability to
modulate mTOR signaling.
While its role in regulating inflammation and immunity via mTOR is an
intriguing possibility, a perhaps more clinically relevant and important avenue to
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consider is the role TIPE2 may play in regulating diabetes and obesity. TIPE2 is
a regulator of the mTOR nutrient sensing pathway, and is in turn regulated by
inflammatory

signals

(see

Chapter

2)

which

down-regulate

TIPE2

expression. Obesity and type II diabetes have a strong correlation between
excessive inflammation and dysregulated nutrient signaling.

While some

molecular pathways that connect these two themes have been discovered, such
as the inflammation induced JNK mediated inhibitory phosphorylation of IRS1,
the precise connection between inflammation and metabolic syndrome is
incompletely understood. While it is primarily expressed within the immune
system, TIPE2 is expressed in both liver and skeletal muscle (Zhang 2011), both
extremely important insulin responsive tissues, which can become insulin
resistant if proper homeostatic regulation is lost. The putative role for TIPE2 as a
regulator of metabolic syndrome will be a line of work worth investigating in the
future.
In addition to its potential role in connecting inflammation with nutrient
signaling, TIPE2 may also play an important role in atherosclerotic plaque
formation and the subsequent heart disease caused by said plaque
formation.

Like diabetes and insulin resistance, atherosclerosis is highly

associated with inflammation. One key component of atherosclerotic plaques is
deposited foam cells, which are macrophages engorged with cholesterol that
become sticky and adhere to the vascular endothelium, constricting blood flow
and eventually causing a blockage. A recent report has indicated that inhibition
of mTOR during foam cell formation can reduce at least some aspects of foam
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cell formation (Yu 2011). Considering that TIPE2 negatively regulates mTOR,
and is itself negatively regulated by inflammatory signals, and that TIPE2 is
highly expressed in macrophages, it could prove to be worthwhile to investigate
the putative role of TIPE2 in foam cell formation.
By providing a new and exciting linkage between inflammation and the
primary nutrient and metabolic signaling pathway within the cell, TIPE2 holds a
great deal of promise as a potential druggable target to treat plethora of diseases
that currently ail millions of people.
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Figure 4.1 Mechanistic diagram of mTORC1 and mTORC2 complexes. GBL and
the recently discovered inhibitor DEPTOR are constant members of each
complex. Raptor provides the mTORC1 specific scaffolding activity while Rictor
provides mTORC2 specific scaffolding activity.
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Figure 4.2 mTOR Signaling is negatively regulated by TIPE2. A.) TIPE2 was
overexpressed in 293T cells for 24h and the activation status of the downstream
the mTOR effectors 4EBP1 and S6K were assayed via western blot. B.) Bone
marrow derived macrophages were isolated from WT and TIPE2 KO mice as
described in methods. Following culturing BMDM were either treated with
vehicle or LPS for 60 minutes, cells were lysed and the activation status of AKT
at S473 was assayed via western blot. C.) TIPE2 was overexpressed in 293T
cells with or without co-expression of RGL for 24h. The activation state of S6, a
target of the mTOR effector S6K was assayed via western blot.
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Figure 4.3 TIPE2 Co-Immunoprecipitates with GBL. Flag-tagged TIPE2 and HAtagged GBL were co-expressed in 293T cells for 24h. Following lysis, lysates
were cleared of the insoluble fraction, and were incubated with either anti-flag or
anti mouse IgG for 2h at 4oC. After a two hour incubation protein G agarose
beads were added to the lysate in order to immunoprecipate all Ig bound protein.
Following a 2h incubation with beads protein was eluted and assayed via
western blot.
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Figure 4.4 TIPE2 Regulates Rictor. A.) Bone marrow derived macrophages were
isolated from WT and TIPE2 KO mice as described in methods.

Following

culturing cells were lysed and assayed via western blot to compare Rictor levels.
Lysates were pooled from 3 animals. B.) 293T cells were either transfected with
TIPE2 alone, or co-transfected with TIPE2 and one of the following plasmids;
Raptor, Rictor, and GBL for 24h. Following transfection cells were lysed and
lysates were analyzed via western blot to compare the effect of TIPE2 on
different members of mTOR complexes.
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Figure 4.5 TIPE2 specifially affects Rictor levels independently of cell death.
293T cells were either treated with etoposide 10 uM 14h or transfected with
TIPE2 24h. Following treatment cells were lysed and lysates were analyzed by
western blot for the effect of death on Rictor levels.
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Figure 4.6 Proposed mechanism of TIPE2 Regulation of mTOR Signaling. Upon
activation TIPE2 sequesters GBL away from mTOR complexes, resulting in the
destabilization of mTORC2 and the subsequent destruction of Rictor and a loss
of function in the mTORC2 complex.
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Chapter 5
TIPE2 and Cell
Death

Work from this chapter is from:
*Gus-Brautbar, *Y., Johnson, D., Zhang, L., Sun,H., Wang, P., Zhang, S., Zhang,
L., and Chen, Y.H. (2012). The anti-inflammatory TIPE2 is an inhibitor of
the oncogenic Ras. Molecular Cell 45, 610–618.
*These authors contributed equally to this work
Along with additional unpublished work, intended for publication in the near
future.
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Abstract
Cell death is a central process crucial to the proper functioning of the
immune system; and dysregulation of cell death can result in diseases of both
severe inflammation and immunodeficiency. TIPE2 has been previously shown
to regulate AICD in CD4+ murine T cells. Additionally a role for TIPE2 in the AKT
and mTOR pathways, both crucial for survival has been established. Here the
role of TIPE2 in regulating cell death was investigated. Overexpression of TIPE2
is toxic to cells in a dose dependent manner. Coexpression of TIPE2 alongside
RGL1, AKT, PDK1, or mTOR, had the effect of reducing TIPE2 mediated cell
death. Surprisingly S6K enhanced TIPE2 mediated cell death, indicating that it
may play a role in activation of TIPE2. Even more surprisingly when TIPE2 is
coexpressed with RGL1 and the GBL subunit of the mTOR pathway a massive
amount of cell death is induced, indicating that TIPE2 may play a role in
connecting the Ral and mTOR pathways.
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Introduction
Cell death is a fundamental biological process that is highly regulated and
absolutely crucial for the proper development and functioning of all multi cellular
organisms. When the death machinery is not functioning appropriately multiple
different disease states can arise, many of which are related to a loss of control
within the immune system.
In a typical immunological response to a foreign antigen, the immune
system will first recognize the presence of a foreign invader, it will make a
decision as to the best way to combat this foreign invader, it will begin to multiply
whatever specific pieces of the immune system are needed to combat the
invader (T Cells, B Cells, etc.), and following clearance of the foreign antigen the
immune system will allow for the orderly destruction of the majority of the newly
created immune cells (Figure 5.1). If these immune cells fail to properly die off,
they can begin to non-specifically attack any number of host cells within the
body, causing a variety of inflammatory disease (Chen 2011).
Within T cells a common function known as activation-induced-cell-death
is a well characterized process in which a T cell that is subject to multiple
stimulations of its T cell receptor undergoes apoptosis and commits suicide
(Ashwell 1987, Smith 1989). This functions as a form of protection since a T cell
which is routinely encountering its cognate antigen is far more likely to be
attacking a “self” molecule, instead of a foreign invader. The primary way in
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which this occurs is via Fas/FasL (discussed in Nagata 1997 and Maher 2002).
Upon activation a T cell will upregulate Fas, which is a cell surface protein which,
when bound by Fas ligand (FasL) rapidly induces apoptosis within the cell.
Additional mechanisms of AICD may include p73, IkBaM, TRAIL, and Bim
(Reviewed in Strasser 2009, Kaufmann 2011).
Types of Cell Death
Cell death is a complicated process, and there are multiple types of cell
death. The differing types of cell death can be divided into one of three general
categories; apoptosis, necrosis, and autophagic cell death.
Apoptosis is a type of programmed cell death in which a suicide program is
activated by the cell. Apoptosis can be triggered by several different pathways,
but is morphologically characterized by several distinct steps:
1.) Cell Shrinking and rounding.
2.) Condensation of the chromatin.
3.) Fragmentation of the DNA in the nucleus.
4.) Breakdown of the plasma membrane and budding away into “blebs”.
5.) Cellular contents are loaded into and removed by the blebs, to later be
phagocytosed and recycled.
In a human billions of cells self-terminate by apoptosis each and every day
(Elmore 2007). If cells become defective and unable to properly apoptose, a
variety of diseases can result. Some of these include autoimmune and
inflammatory diseases if the immune system cannot properly induce apoptosis in
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inflammation producing cells (Chen 2011). Numerous forms of cancer can also
result from incomplete or ineffective apoptosis (Cotter 2009). If cells apoptose too
easily certain types of neurodegenerative disease may result, as well as
immunodeficiency.
While apoptosis is a type of pre-programmed cellular suicide that all cells
are capable of undergoing, necrosis is an “unplanned” form of cell death in which
acute injury or toxicity causes the cell to die catastrophically. The end result of
apoptosis is the loading of cellular contents into small blebs of membrane, to be
later phagocytosed and recycled, while the end result of necrosis is usually an
uncontrolled spillage of cellular contents into the general circulation.

This

uncontrolled spillage can have varying effects, amongst them it can be highly
toxic to adjacent cells, and can also be highly immunogenic. Morphologically
necrotic cells oftentimes appear to be swollen and puffy. This is due to a lack of
cohesion off their plasma membrane, and they become swollen full of fluid.
Autophagy is a catabolic process whereby a cell will begin to degrade its
own internal components in order to generate essential nutrients. This most
often occurs in response to starvation or stress within the cell. While a variety of
autophagic processes and triggers exist, they all result in the degradation of
internal proteins and organelles by the lysosome.

While autophagy always

occurs at a low basal level, under certain conditions such as starvation or stress
it can be upregulated to cause a larger bulk degradation. In many circumstances
a large buildup of autophagosomes, as well as heavy upregulation of autophagic
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machinery is strongly correlated with cell death (Codogo 2005, Tsujimoto 2005).
It is still not entirely clear exactly how autophagy can cause cell death.
TIPE2 has previously been established to regulate AICD in primary murine
CD4+ T cells (Sun 2008). Due to the central role of appropriate cell death in
regulating the immune system, as well as the central role of TIPE2 in regulating
the immune system, the role of TIPE2 in regulating cell death was investigated.

108 | P a g e

Materials & Methods
Cell Lines and Plasmids
RAW 264.7 and HEK 293T cells were purchased from ATCC. Cells were
grown

in

DMEM

supplemented

with

10%

FBS,

penicillin

and

streptomycin. mTOR, Rictor, Raptor, myr pdk1, AKT, S6K1, and S6K2 plasmids
were purchased from Addgene. TIPE2-Flag plasmid was used as previously
described (Sun 2008).

Cell Death Quantification
The 293T cells, 0.5x10 /dish, were plated in 6-cm dishes and transfected
6

with various plasmids. All transfections were carried out using FugeneHD
reagent (Roche) according to the manufacturer’s instructions. 24 hrs later,
supernatant was collected, and adherent cells were trypsinized and mixed with
the supernatant. Cells were centrifuged (1000 rpm, 10 minutes), resuspended in
equal volume of media, and stained with trypan blue. Dead and live cells were
counted on a hemocytometer. Four fields of the hemocytometer were counted
and then averaged for each sample.

Etoposide Treatment
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Etoposide was purchased from Sigma (St. Louis, MO) part #E1383-25MG.
Cells were treated with 50 uM etoposide for the indicated times.

Immunoblotting
Cells were lysed in Cell Lytic M cell lysis buffer (Sigma St. Louis, MO) and
total protein concentration determined via Bradford analysis. 30 g protein was
loaded to each lane, and separated by SDS-PAGE. Protein was transferred to a
nitrocellulose membrane, and was blocked with 5% milk in TBST.

The

membrane was then probed with the following primary antibodies overnight at 4
0

C: Phospho–AKT (Serine 473, 1:1000, Cell signaling), total AKT (1:1000, Cell

Signaling), Myc (1:1000 Cell Signaling), Flag (1:1000, Sigma. Detection was
performed using enhanced chemiluminescence of HRP-conjugated secondary
antibodies (anti-mouse or anti-rabbit IgG, 1:1000, GE healthcare).
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Results
An initial observation was made that TIPE2 expression is upregulated in
dying cells (Figure 5.2). Since TIPE2 could either be upregulated to assist in
inducing cell death, or could be a protective protein upregulated in order to try to
save dying cells, this effect was further investigated.

In order to determine the

role of TIPE2 in regulating cell death, flag tagged TIPE2 was overexpressed at
increasing concentration in HEK 293T cells, and cell death was quantified at 24
hours (Figure 5.3). Overexpression of TIPE2 killed cells in a dose dependent
manner. In order to identify which pathway(s) TIPE2 was affecting in order to kill
cells, TIPE2 was co-transfected alongside multiple constructs expressing genes
from both the Ral and mTOR pathways which TIPE2 has previously been linked
to (see chapters 3 and 4 of this dissertation for more information on these
pathways). Since Ral has been linked to numerous survival and proliferation
pathways,TIPE2 was first co-expressed alongside Ral A and Ral B, these protein
failed to compensate for TIPE 2 induced death. In order to ensure that both of
the Ral Isoforms were active, constitutively active forms of both Ral A and Ral B
were also co-expressed alongside TIPE2 (Figure 5.4A). These also failed to
provide any rescue from TIPE2 induced death. Because TIPE2 inhibits RGL1,
and RGL1 has other functions in addition to acting as a RalGEF, TIPE2 was
coexpressed alongside RGL1, which provided a rescue of approximately 60% of
the TIPE2 induced death (Figure 5.4B). Since RGL provided a rescue, and
because RGL1 can function as a scaffold to bring PDK1 into contact with its
target AKT, we next decided to test if active forms of PDK1 and AKT were
capable of rescuing from TIPE2 induced cell death (Figure 5.4A).

Both

myristolated PDK1 (an activating mutation) and a constitutively active AKT were
capable of providing a rescue from TIPE2 induced cell death equal to that of
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RGL1. To confirm that the scaffolding activity of RGL1 was necessary for rescue
from TIPE2 induced cell death a mutant of RGL1 was created in which the N
terminus was truncated. The N terminus of RGL1 is required to scaffold for
PDK1 and AKT, but is not required for its GEF activity. This N terminal deletion
mutant which could not activate AKT was also not able to rescue from TIPE2
induced cell death (Figure 5.4B). Finally, in order to confirm the central
importance of dysregulated AKT in TIPE2 induced cell death, a dominant
negative construct of AKT was coexpressed alongside TIPE2 (Figure 5.5A). If
TIPE2 were killing in an AKT independent fashion, death induced by a dominant
negative AKT would be additive with death induced by TIPE2. If TIPE2 were
killing via inhibition of AKT, expression of TIPE2 alongside dominant negative
AKT should provide no further cell death over dominant negative AKT
alone. These conditions were tested and there was no additive effect, indicating
that TIPE2’s ability to kill cells is via its inhibition of AKT. To further confirm the
central role of AKT in regulating TIPE2 induced cell death, the level of AKT
phosphorylation was checked in a variety of rescue conditions (Figure 5.5B),
further supporting the importance of AKT.
While the activation of AKT by RGL1 is always occurring in cells, the
primary method by which AKT is activated is via the MTORC2 complex, which is
a complex composed of mTOR, GBL, Rictor, Protor, and Sin1. Since TIPE2 has
a negative regulatory effect that occurs intermittently with mTOR, and always
with Rictor, we needed to determine if this method of AKT activation was also
involved in TIPE2 induced cell death. Overexpression of mTOR alongside TIPE2
rescues cells from death to a similar degree as RGL1, active AKT, and
myristolyated PDK1 (Figure 5.4A). Since AKT can lie both upstream and
downstream of mTOR, depending on which cellular signaling events are active at
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any given time, we decided to test some additional downstream mTOR
substrates in order to try to further hone in on which pathways were being
dysregulated by TIPE2. p70S6K is a well-known and studied downstream mTOR
effector. It is involved in ribosome biogenesis and protein synthesis, and lack of
all S6K isoforms leads to marked reduction in viability (Pende 2004). While we
hypothesized the co-expression of TIPE2 and S6K would either help to rescue
from TIPE2 induced death, or have no effect, S6K and TIPE2 co expression
instead increased cellular death (Figure 5.6). This effect was unexpected, so all
previous rescue experiments were repeated, and only RGL1 could provide a
slight rescue from TIPE2+S6K induced death (Figure 5.7). TIPE2+S6K+mTOR
actually led to slightly more death than TIPE2+S6K alone (Figure 5.7).
In order to identify the type of death occurring in cells transfected with
TIPE2, lysates were checked for cleaved caspase 3 and supernatant was
checked for HMGB1. Neither was readily detectable indicating that cell death
was not occurring via a canonical apoptotic or necrotic pathway.
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Discussion
TIPE2 induces death in cells, and the mode of killing was investigated via
two different approaches. The first approach was to check for common apoptotic
(cleaved caspase 3) and necrotic (HMGB1) markers in order to identify what type
of cell death TIPE2 was inducing. Neither cleaved caspase 3 nor HMGB1 were
readily detectable, indicating that a third type of cell death, or a combination of
different types of death are occurring in cells overexpressing TIPE2.
The second approach was to use co-expression analysis in order to
identify which signaling pathway(s) were involved in TIPE2 induced cell
death. Full Length RGL1 as well as a variety of truncation mutants were coexpressed alongside TIPE2, but only full length RGL1 was capable of rescuing
from TIPE2 induced cell death. Since full length RGL1 can function as both a
GEF and a scaffold, each function had to be tested in order to see which was
responsible for rescuing from TIPE2 induced cellular death. In order to test
whether GEF activity was responsible for the rescue an RGL mutant was created
lacking the N-terminal region, which functions as an autoinhibitory region of RGL,
resulting in an RGL mutant with higher than normal GEF activity. This region is
also crucial for RGL scaffolding activity.

In addition both wild type and

constitutively active forms of Ral A and Ral B were co-expressed alongside
TIPE2. Neither of these approaches were able to rescue from TIPE2 induced
cell death (Figure 5.4), indicating that despite the well-known pro-survival
functions of the Ral proteins, that TIPE2 mediated inhibition of RGL GEF
function, and thus downstream Ral A and Ral B activity, were not responsible for
the TIPE2 induced cell death. With inhibition of the GEF activity of RGL ruled out
as the method by which TIPE2 induces cell death, it was next necessary to
determine that RGL1 scaffolding activity was responsible for this function.
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We had already established that TIPE2 disrupts the scaffolding activity of
RGL (figure 3.5), which brings the kinase PDK1 into close contact with its target
AKT, allowing AKT to become phosphorylated and activated. In order to assess
whether loss of PDK1/AKT was responsible for TIPE2 causing the death that it
does, active forms of AKT and PDK1 were co-expressed alongside TIPE2. Both
active AKT and PDK1 rescued from cell death to the same degree as RGL1,
indicating that the AKT pathway was likely involved.
In order to further confirm that TIPE2 induced death was occurring through
the AKT pathway, TIPE2 was co-expressed alongside dominant negative AKT. If
TIPE2 were killing via a means other than AKT, TIPE2 expressed alongside
dominant negative AKT would show an additive effect on total cell
death. Alternatively, if TIPE2 were killing via inhibition of AKT, then expressing a
dominant negative AKT alongside TIPE2 should not induce any additional cell
death. The addition of dominant negative AKT to TIPE2 resulted in no additional
cell death, confirming that TIPE2 kills via inhibition of the AKT pathway.
mTOR, another activator of AKT can also rescue from TIPE2 induced cell
death, further supporting the idea that inhibition of the AKT pathway is how
TIPE2 is killing cells. A dosage of TIPE2 corresponding to 1.5ug on the dose
response curve in Figure 5.3 was used for nearly all of the signaling assays
performed earlier in this work.

Taken together, these data indicate that

dysregulation of the AKT pathway, at least partially by inhibiting PDK1/AKT
scaffolding provided by RGL, is responsible for the TIPE2 death effect on cells.
P70S6K is a kinase that transduces downstream signals to induce
anabolism, cell growth, and protein synthesis. When overexpressed in cells, it
confers a survival advantage to cells, but paradoxically when co-expressed
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alongside TIPE2 it has a synergistic effect in which cell death with TIPE2+S6K is
more severe than with TIPE2 alone. Co-expression of mTOR, the upstream
activator of S6K, alongside S6K and TIPE2 results in an increase in death over
TIPE2+S6K, despite the fact that mTOR co-expression alongside TIPE2 heavily
reduces death induced by TIPE2. These data, taken together, indicate that S6K
may be functioning as an upstream activator of the TIPE2 death “function”.
GBL and RGL are both proteins that TIPE2 interacts with and neither of
which cause any toxicity to cells when expressed on their own or together. When
co-expressed alongside TIPE2 however they induce a large amount of cell death.
This is despite the fact that RGL can rescue from TIPE2 cell death when coexpressed individually alongside TIPE2.

This indicates that TIPE2 may

somehow be serving as a bridge between the mTOR and RAL pathways,
possibly affecting AKT from two different directions. Additionally both mTOR and
Ral can affect autophagy.

Ral signaling promotes autophagy while mTOR

signaling inhibits autophagy.

It is possible that the cellular death seen from

TIPE2 is from the interface of these two pathways, confusing the cell with both
pro- and anti- autophagic signals.

Therefore it is possible that TIPE2 induces

some sort of autophagic cell death. More work will need to be completed in order
to be certain of this.
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Figure 5.1 Mechanism of how lymphocytes respond to antigenic challenge, divide, and
then die off.
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Figure 5.2 Association of TIPE2 Expression with Cell Death. RAW 264.7 macrophage
were given a toxic amount of etoposide in order to induce apoptosis (Knethen 1998), and
lysates were collected over time and TIPE2 message levels were checked with real time
PCR.
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Figure 5.3 Overexpression of TIPE2 induces Cell Death. Increasing amounts of TIPE2
were overexpressed in 293T for 24 hours. Death was assayed at 24 hours via trypan blue
staining.
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Figure 5.4 Rescue of TIPE2 Induced Death. A.) TIPE2 was transfected alone or with
various plasmids from identified affected pathways. After 24h cell death was assayed
using trypan blue staining. B.) TIPE2 death is rescued by full length RGL, but is no
longer able to be rescued by an N-terminal truncation mutant that lacks the ability to bind
to and scaffold for PDK1. C.) Western blot analysis of certain samples from A and B
above showing a correlation between AKT phosphorylation and rescue from TIPE2
induced death.
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Figure 5.5 TIPE2 affects death by regulating the AKT pathway. A.) TIPE2 was
expressed alone or alongside dominant negative AKT and cell death was quantified using
Trypan Blue staining. B.) TIPE2 was coexpressed alongside various RGL constructs
and levels of phosphorylated AKT (S473) were measured via western blotting.
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5.6 S6K and TIPE2 Induce more Cell Death than TIPE2 alone.

293T cells were

transfected with either TIPE2, S6K1, or TIPE2+S6K1. 24 hours after transfection cell
death was assayed using Trypan blue staining.
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Figure 5.7 S6K and TIPE2 Rescue Attempts. TIPE2 and S6K1 were cotransfected
alongside all plasmids which are capable of preventing TIPE2 –only induced cell death.
AKT and PDK1 had no effect, while RGL1 still maintained a small rescue effect even in
the presence of S6K. mTOR exacerbated the TIPE2+S6K death effect.
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Figure 5.8 Compilation of S6K and TIPE2 Death Effects.
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5.9

RGL and GBL synergize to cause cell death with TIPE2.

293T cells were

transfected with either vector, TIPE2 alone, or TIPE2 with GBL and RGL1. After 24h
transfection time cell death was measured using Trypan blue staining.
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Chapter 6
General Discussion
and Future
Directions
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The field of immunity and inflammation has changed tremendously over
the past decade, and will continue to change at an ever increasing pace of
discovery. TIPE2 plays a central role in regulation of the immune system, and is
slowly garnering increased attention for this role.
Understanding how TIPE2 is regulated is crucial towards creating
therapies around the immunomodulatory function of TIPE2. Depending upon the
pathologic condition it may be desired to either have more or less TIPE2
expressed. For instance as a cancer treatment the expression of TIPE2 could be
beneficial to either kill tumors, or to prevent them from metastasizing. In various
types of immunodeficiency however, a reduction in TIPE2 level may be
warranted, in order to reduce unnecessary death of lymphocytes. In chapter 2
we provided data indicating that TIPE2 is regulated at both the message and
protein levels. TIPE2 message is likely regulated by an NF-KB induced
microRNA, which further work in the lab has indicated is likely mir21. At the
protein level TIPE2 interacts with TRCP, and this interaction seems to be
increased under conditions in which reduced TIPE2 protein is present in the
lysate. These data, taken together, indicate that the SCF-TRCP complex is the
likely E3 ligase complex responsible for the destruction of TIPE2 protein.
Since TIPE2 levels drop at both the protein and nucleic acid level in
response to detecting inflammation, the role of TIPE2 as a suppressor of
inflammatory programming has been supported by this regulation profile. Data
from human hepatocellular carcinoma patients from chapter 3 demonstrates that
TIPE2 expression in non-immune tissues can minimally correlate, if not play a
causative role in hepatocellular carcinoma.

This may indicate a potential

diagnostic role for TIPE2, using TIPE2 expression as an indicator for
carcinogenesis, and possibly metastasis of transformed cells.
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With this newfound knowledge of the dual forms of TIPE2 regulation, new
treatments can be devised to specifically target TIPE2 levels within various cell
types, either promoting or reducing TIPE2 stability. Likewise current drugs can
now be reassessed for their effect on TIPE2 expression, possibly allowing for
more effective use of said therapies. Hopefully this knowledge will result in a
series of viable treatments with which to treat a wide array of different diseases.
Mechanistically TIPE2 appears to modulate the immune system (as well
as other cell types and tissues within the body), by regulating key cellular
processes involved in metabolism, survival, and polarization. By binding to
RGL1 (and other RalGDS family members) TIPE2 is capable of exerting
numerous potent effects on the cell, some of which are only in the infant stages
of study. By binding RGL1 TIPE2 first and foremost prevents Ras from binding
to and activating RGL1, thus inhibiting the activation of the small GTPase RalA
and RalB. These GTPases are extremely pleiotropic, and could most aptly be
described as regulators of polarization, although the reach of their regulatory
events has a hand in nearly every cellular process. RalA is more heavily
involved in polarized exocytosis as well as anchorage independent growth, while
RalB has been more heavily tied to cell survival. Rapid polarization and
recruitment of appropriate membrane proteins and remodeling of the actin
cytoskeleton are hallmarks of all cells of the immune system.

Without the

capacity to modulate these factors the immune system would lack the plasticity
required to rapidly adapt to constant onslaught of pathogens it faces.

The

connection between TIPE2 modulating the immune system via Ral is thus an
obvious one, and future work will be required in order to truly tease apart
just how vital the Ral proteins are to the proper functioning of the immune
system. What is truly striking about TIPE2 however, is that it affects polarization
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in multiple ways. In addition to inhibiting the activation of the Ral family of small
GTPases, TIPE2 also binds to and inhibits the Rac1 small GTPase. Similar to
the Ral proteins, Rac1 is a pleiotropic molecule with many downstream effectors,
regulating processes as divergent (and important) as cell growth, adhesion, and
motility. Rac1 additionally imparts a marked level of regulation upon the actin
cytoskeleton, much like Ral A and B. Since the immune system by its very
nature is migrating throughout the body and sampling the environment,
molecules such as TIPE2 that regulate both the processes of sampling and
migration are likely key central regulators for all of these cells.
Beyond its effect on the Ral proteins, the TIPE2 mediated inhibition of
RGL1 reduces another important RalGDS family function, the scaffolding activity
it performs to link PDK1 to its downstream kinase AKT. Being a central regulator
of cell survival, the TIPE2 mediated reduction in AKT activation is a very
important signaling event. TIPE2 is also connected to AKT via several other
pathways. The TIPE2 binding partner Rac1 can interact with the kinase mTOR,
which falls both upstream and downstream of AKT, and thus can both activate
AKT and be activated by AKT. TIPE2 itself can weakly IP with mTOR, possibly
via using Rac1 as an intermediary.

And finally, and most importantly, TIPE2

interacts with GBL, the constant subunit of both mTOR signaling complexes.
The mTORC2 complex is the primary upstream kinase of AKT, and a key
component of this complex is the scaffold Rictor. TIPE2 markedly affects the
level of Rictor present in cells, with overexpression of TIPE2 reducing it, and
knockout cells showing increased levels.

The most likely reason for this

destruction is that TIPE2 sequesters GBL away from mTORC2 complexes,
resulting in the destabilization of the complex and the subsequent proteolytic
destruction of Rictor. GBL knockout MEFs have been shown to have this precise
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phenotype. The GBL sequestration mediated destruction of Rictor has yet
to be demonstrated however, and will need to be completed in the future.
An additional possibility is that TIPE2 could bind and sequester away Sin1,
another protein that when lost can cause a loss of Rictor. Unpublished
data from the Chen lab indicates that TIPE2 can interact with phosphatidic
acid (PA).

Since mTOR functions as a sensor for this molecule, it is

possible that TIPE2 can also intersect with the mTOR pathway by binding
to PA and modulating how mTOR can interact with the crucial signaling
lipid. As reported in Chapter 3, the entire mTOR pathway, which is regulated by
TIPE2, is extremely crucial for the proper function and response of the immune
system. With the affect that mTOR modulation has on appropriate T and B cell
differentiation into effector and memory cells, TIPE2 levels or activation may
provide a key target during vaccinations in order to generate more robust
memory cell production. To date nothing is known about TIPE2 and B Cell
function, and this will have to be further studies in the future.

It is also

important to take note that overexpression of TIPE2 causes a loss of
Rictor, and it can also, in certain conditions, cause a loss of mTOR and of
RGL. It is thus possible that TIPE2 has some sort of degradatory function,
or links certain target proteins to the cellular destruction apparatus. This
will require further investigation to deduce how these TIPE2 binding
partners or pathway partners are being degraded by the cell.
With the mechanistic data presented so far it is easy to imagine how and
why TIPE2 has such a dramatic effect on the regulation of the immune system.
By affecting polarization via Rac and Ral, and by affecting the metabolic state via
mTOR regulation, TIPE2 would have a dramatic effect on say, the proper
expression of homing receptors and thus proper trafficking of a lymphocyte. Or,
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perhaps, the proper recognition and engulfment of a particle, and acidification of
a phagolysosome during phagocytosis. (Both of these phenotypes do occur).
What is truly interesting though, are the effects of TIPE2 in the non-immune
system. While not all cell types express TIPE2, some do, and most express at
least one of the TNFAIP8 family members, each of which share high homology
with one another. As we see in Chapter 3, TIPE2 is expressed by healthy liver
cells, and appears to be silenced by transformed liver cells within the tumor.
Since no spontaneous tumors have ever developed in knockout mice, this would
imply that (at least in certain tissues) loss of TIPE2 is a necessary but not
sufficient step to induce tumor formation. This makes assaying for TIPE2 levels
a fantastic early diagnostic indicator for “at risk” cells. Reintroduction of TIPE2
may also be able to destroy already formed tumors. When it comes to cancer
however, the effect of TIPE2 would seem to truly be central to metastasis, much
more so than tumor formation itself. With TIPE2 regulating pathways involved in
survival, metabolism, polarization, motility, and anchorage independent growth,
TIPE2 literally regulates everything needed for effective metastasis.

Thus,

TIPE2 as a diagnostic may not only provide information regarding tumor
formation, but may also provide extremely crucial diagnosis indicating likely
metastasis. And again, an ability to reintroduce TIPE2, even if it were not able to
destroy a solid tumor, may prevent that tumor from metastasizing and thus
prevent the lion’s share of damage and death associated with cancer
progression. More work with human tissues will be required to provide a
definitive link between TIPE2 and cancer metastasis.
It is also important to note that TIPE2 is associated with and regulated by
inflammation, and in turn heavily regulates the mTOR pathway. Dysregulation of
mTOR signaling as well as inflammation are both highly correlated with type II
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diabetes and obesity. It would be foolish to not investigate the potential role
of TIPE2 in functioning as a bridge between inflammation and mTOR, thus
possibly providing a new and unknown link between inflammation and
nutrient signaling, and possibly providing us with another potential
druggable target in the war against metabolic syndrome.
Also important to note is that when RGL is coexpressed alongside GBL
there is no perceived change in any cell viability or health measure. When TIPE2
is cotransfected alongside these two proteins they synergize and kill cells to an
extremely high degree, much higher than TIPE2 alone. Thus, it is possible that
TIPE2 function as a bridge between the mTOR and Ral Signaling pathways,
quite possibly by nucleating the formation of a new complex. The potential
for a complex of this sort has particularly important ramifications on how
we interpret autophagy in the future, since mTOR is a very strong negative
regulator of autophagy, while Ral is a very strong positive regulator of
autophagy. It is possible that TIPE2 is the critical piece that links these two
pathways and thus determines whether autophagy should be initiated or
not. TIPE2 cell death may thus be some sort of autophagic death due to it
confusing the cell’s normal autophagy system. This will require further
investigation.
It is rather remarkable that TIPE2 manages to regulate AKT via 3 putative
mechanisms and on both of its activating residues. TIPE2 regulates the PDK1
mediated phosphorylation of T308 by inhibiting the scaffolding function of the
RalGDS family, TIPE2 potentially affects mTOR itself via Rac1 or via direct
binding, and TIPE2 negatively regulates the Rictor subunit of mTORC2, possibly
via GBL sequestration. While the importance of AKT cannot be understated, the
TIPE2 expression profile when viewed through the prism of cell survival and
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metabolic regulation offered by AKT offers an interesting perspective on the role
and purpose of TIPE2 within the immune system. To use a monocyte as an
example; before activation a monocyte is primarily at rest, migrating through the
body and sampling the environment. At this stage in the life of the monocyte
TIPE2 is highly expressed, though not toxic, it is only offering a repressive
function, preventing the monocyte from becoming highly active, creating a
respiratory burst, etc.

Upon activation the monocyte rapidly and specifically

downregulates TIPE2 expression at both the message and protein level. With
TIPE2 no longer present to inhibit metabolism via mTOR, and polarization via Ral
and Rac1 the monocyte is free to rapidly migrate, express chemotactic receptors
on its surface, and undergo heavily metabolic events like a respiratory burst.
After some amount of time – which we have yet to determine experimentally in
primary cells – TIPE2 expression is restored. In the now activated monocytes
however, TIPE2 is no longer simply repressive, but toxic.

This effect is

supported by the fact that serum starving TIPE2 overexpressing cells halts any
TIPE2 toxicity despite not affecting expression. Additionally TIPE2 only appears
to be toxic in active and dividing cells. Cells transfected with TIPE2 that are
already dense no longer die en masse, despite equal or greater levels of TIPE2
being expressed in the dense cells.

More work will need to be done to

support this theory, such as fully tracking TIPE2 expression levels in
primary cells, and using a variety of artificial activation conditions in
conjunction with TIPE2 expression in order to fine tune exactly when and
under what conditions TIPE2 proves to be toxic to cells, instead of just
inhibitory.
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TIPE2 seems to regulate polarization and metabolism in multiple and
important ways. These modes of regulation give TIPE2 a role in the regulation of
cell survival, and motility. They provide a link between TIPE2 and cancer, and
TIPE2 may minimally serve as a diagnostic indicator of transformation and
metastasis, if not become a bona fide treatment for these stages of cancer
development. TIPE2 regulation of mTOR and Ral have positioned it at a unique
crossroads between “go” and “no go” signals for the progression of autophagy.
This may result in TIPE2 playing a central role as an autophagic switch (Figure
6.1). Finally TIPE2 may be performing a function similar to AICD, in which it
proves toxic to cells that have been activated, thus preventing a buildup of
inflammation producing monocytes and lymphocytes following antigenic
challenge and clearance.

In conclusion we have only begun to scratch the

surface of TIPE2 biology and its numerous functions within both the cell and the
body. It will prove very interesting to see what we can take from TIPE2 in order
to advance medical science and dramatically improve the health of people in the
future.
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Figure 6.1 TIPE2 may function as an autophagy Switch. Since TIPE2 is capable
of inhibiting the anti-autophagy mTOR pathway, and the pro autophagy Ral
pathway, and TIPE2 clearly connects these two pathways via strange and
incompletely defined phenotypes (chapter 4, chapter 5), it may function as a
switch which is either actively inhibiting either mTOR in order to promote
autophagy within the cell, or inhibit Ral in order to prevent autophagy within the
cell.
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Figure 6.2 Cluster Map of TIPE2 interactions, functions, and potential functions.
TIPE2 and RGL functions are highlighted in green, mTOR in red, and Rac1 in
blue. Different potential diseases and therapies to investigate are then blurred by
color based upon which of these pathways feed into them.
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